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Mamma e papà 
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L’inferno dei viventi non è qualcosa che sarà; se ce n’è uno, è 
quello che è già qui, l’inferno che abitiamo tutti i giorni, che 
formiamo stando insieme. Due modi ci sono per non soffrirne. 
Il primo riesce facile a molti: accettare l’inferno e diventarne parte 
fino al punto di non vederlo più. Il secondo è rischioso ed esige 
attenzione e apprendimento continui: cercare e saper riconoscere 
chi e cosa, in mezzo all’inferno, non è inferno, e farlo durare, 
e dargli spazio. 
 
    Italo Calvino, LE CITTA’ INVISIBILI 
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ABSTRACT 
 
Bovine mastitis is one of the most significant causes of economic losses for the dairy 
industry. On the other hand, public health authorities advise prudent use of antibiotics 
because they could promote bacterial resistance and leave residues in food chain. The 
dairy industry could benefit from the development of safe antimicrobial agents and 
bacteriocins could be attractive alternatives to antibiotics. Due to the safety of Lactic acid 
bacteria (LAB), their bacteriocins have the potential to be used as antimicrobials in 
veterinary clinical application. We analyzed the efficacy of antibacterial substances 
produced by bacteriocinogenic Lactococcus lactis subsp. lactis strains against contagious 
and environmental mastitis pathogens. Thereafter, we investigated how lactococcal 
strains or their bacteriocins could influence mammary gland innate immune response in 
vitro. Out of 65 LAB strains tested, 3 were active against mastitis pathogens: 2 strains 
produced Nisin, one Lacticin 481 and in addition a novel molecule with likely antibacterial 
activity. To analyze the immune response of mammary epithelial cells when stimulated 
with lactococcal strains or bacteriocins, a stabilized epithelial cell line, BME-UV1, was 
used. Both lactococcal live cultures and their antibacterial products were shown to 
modulate the non-specific immune response of BME-UV1 cells: Lysozyme and N-acetil-β-
D-glucosaminidase excretion were overall enhanced by bacteriocins and live-culture 
treatments, while intracellular amounts were unaffected by treatments. Proinflammatory 
cytokine expression of treated BME-UV1 was similar to that observed in control cells, 
except for Lactococcus lactis subsp. lactis SL153. Such strain induced a significant 
reduction of TNFα transcriptional level. 
The stimulation of enzyme secretion due to the administration of lactococci or of their 
antibacterial products, with potential enhancement of pathogens cleaning, can be of 
interest for the prevention of intra mammary infections. In addition, Lactococcus lactis 
subsp. lactis SL153 strain could be advantageous for its potential anti-inflammatory 
properties and could be of interest for the development of intra-mammary probiotic 
treatments. 
Key words: mastitis, bacteriocins, Lactococcus lactis subsp. lactis, antibacterial 
treatments, non-specific immunity. 
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STATE OF THE ART 
 
1. LACTIC ACID BACTERIA (LAB): NOVEL APPLICATIONS IN MASTITIS 
FIELD 
 
1.1. LAB bacteriocins 
The finding of bacteriocin production in several bacterial species has increased 
researchers’ interest to study these new antibacterial molecules. Due to their efficacy 
they are investigated as alternatives to traditional antibiotic treatments both in human 
and veterinary clinical application. 
Bacteriocins are termostable, ribosomally synthesized peptides secreted by many 
varieties of Gram-positive and Gram-negative bacteria, to kill other bacteria. They can be 
active either in the same species (narrow spectrum) or across the genera (broad 
spectrum). Producer organisms are resistant to their own bacteriocin activity, producing 
specific proteins which provide to sequestration or competition for bacterial receptors or 
to pump bacteriocins from the producer membrane (Cotter et al., 2005). It has been 
proposed that 99% of all bacteria may produce at least one bacteriocin; the only reason 
we haven’t isolated more is that few researchers have looked for them (Riley and Wertz, 
2002). In addition to ribosomally synthesized antimicrobial peptides, bacteria also 
produce antibiotic molecules through the activity of some enzymes called nonribosomal-
peptide synthetases wich provide to modify peptides through ring formation, 
glycosylation or acylation. Among this type of antimicrobial peptides polymyxin B and 
gramicidin S have found an application in topical treatment of infections, while 
vancomycin and daptomycin have become important for their efficacy against multiple 
resistant strains of Gram-positive bacteria (Hancock et Sahl, 2006). 
Bacteriocin production provides bacteria a competitive advantage in the environment, 
eliminating competitors, thus gaining resources (Lohans and Vederas, 2012). 
Among producer strains, lactic acid bacteria (LAB) are the mostly investigated because 
they are approved as Generally Recognized As Safe (GRAS) organisms by Food and Drug 
Administration and they are permitted as additives in food. LAB are often found in foods 
and used to manufacture fermented foods, they are known not only to contribute 
improvement of taste, but also to prevent contamination by spoilage bacteria. Especially 
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bacteriocins-producing LAB, which have antibacterial activity, are considered suitable in 
food preservation. On the basis of the safety of LAB, their bacteriocins have the potential 
to be used as antimicrobial in all fields in which safety and absence of residues are 
required. Although pollution of antibiotics in the environment is an emerging problem, 
bacteriocins have proteinaceous nature and they are degraded easily in our body and in 
the environment (Zendo et al., 2010). 
1.1.1. Production and classification 
Bacteriocins are produced as inactive pre-peptides with an N-terminal sequence guide 
(Macwana and Muriana, 2012). These precursors are transported through specific carriers 
at the cell surface during the exponential growth fase and enzymatically converted into 
their active form. Bacteriocin production is managed by a three-component regulation 
system: an inducing peptide (or pheromone-activating factor), the transmembrane 
histidine kinase (pheromone receptor) and a response regulator protein. The inducing 
peptide is the pre-peptide synthesized in the ribosome in small amount. When the 
inducing peptide concentration reaches a threshold level, it activates the trasmembrane 
histidine kinase, which leads to autophosphorylation of the histidine residue, thus 
transferring phosphate to the response regulator protein. The phosphorylated regulator 
activates the transcription of the bacteriocin in addition to the elements that form the 
regulatory system, initiating a positive feedback. In some cases, such as in Nisin, the 
bacteriocins itself exert the induction function, leading an exponential increasing in 
bacteriocin synthesis (Balciunas et al., 2013) 
The classification scheme of LAB bacteriocins has been subjected to ongoing revision, 
Klaenhammer (1993) proposed four classification groups, but recently a new scheme of 
classification was proposed. Class I bacteriocins are the lantibiotics, which are highly post-
translationally modified peptides thermostable and with very low molecular weight (<5 
kDa). Class II consists of small thermostable peptides (<10 kDa) which are free of modified 
residues. A third class (class III bacteriocins) includes non-bacteriocin lytic proteins, 
termed bacteriolysins which are large (>30 kDa) and heat-labile proteins with a distinct 
mechanism of action (Cotter et al., 2005). 
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Class I bacteriocins 
The lantibiotics (lanthionine-containing antibiotics) are small peptides (19–38 amino acids 
in length) containing lanthionine or β-methyllanthionine residues. These unusual residues 
form covalent bridges between amino acids, resulting in internal ‘rings’ and giving 
lantibiotics their characteristic structural features. The lantibiotics carry out their 
antibacterial activity with two different modes of action: either forming pores in the 
membrane of sensitive cells and/or binding lipide II and preventing the formation of 
peptidoglycan (Jung G, 1991). Generally they are active against Gram-positive bacteria, 
but their activity can be extended to Gram-negatives if the integrity of outer membrane 
have been affected (Cotter et al., 2005). 
Among the LAB bacteriocins identified to date, Nisin has been the most investigated. It is 
approved for use as a food preservative since 1969 (Balciunas et al., 2013) and remains 
the only bacteriocin approved for use by the European Union and Food and Drug 
Administration. Several variants of Nisin, which is a 34 amino acids, are produced by 
Lactococcus lactis subsp. lactis. Nisin has a broad-spectrum of activity against strains of 
Gram+ bacteria and exert its activity forming pores in cell membranes even if a secondary 
antimicrobial mechanism has been observed consisting in the inhibition of peptidoglycan 
biosynthesis after Nisin-lipid II binding (Wiedemann et al., 2001). Nisin and Lacticin 3147 
need a docking molecule as initial receptor: the N-terminal binds to a peptidoglycan 
precursor, lipid II, while the C-terminal penetrates cytoplasmic membrane resulting in 
pore formation with the consequent leak of ions and ATP from the cells. Although Nisin is 
primarily active against gram-positive bacteria, some strains can become nisin resistant 
(Mantovani et Russell, 2001). It is thought that there are at least four processes involved 
in nisin resistance: preventing the bacteriocin from reaching the cytoplasmatic 
membrane, reducing the acidity of the extracellular medium thereby stimulating binding 
of bacteriocin to the cell wall, preventing the insertion of the bacteriocin into the cell 
membrane and transporting the peptide out of the membrane (Kramer et al., 2006). It 
should be noted that bacteria differ greatly in their sensitivity to bacteriocins activity, due 
to the differences in cell envelope composition. Alterations within the envelope are 
repeatedly seen in bacteria with altered resistance to Nisin. Kaur et al. (2011) observed 
after repeated exposure to Nisin, changes in cell membrane or cell wall and a nisin-
degrading protease. The cell-wall thickening appears beneficial to nisin-resistance: this 
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thickening seems to protect membrane and lipid II against the Nisin effect (Kramer et al., 
2006). The development of resistance can interestingly bring to negative consequence; 
for example a L. monocytogenes nisin-resistant variant results in an acid -sensitive 
phenotype (McEntire et al., 2004). Naghmouchi et al. (2007) noted that the development 
of bacteriocin resistance can be associated with a cross-resistance among different class 
of bacteriocins. Nevertheless, to several bacteriocins, such as Lacticin 3147, bacteria do 
not readily develop resistance and, when it occurs, it happens at low frequency (Guinane 
et al., 2006). 
 
 
Table 1. Classification of LAB bacteriocins produced by strains belonging to Lactococcus 
spp. (Zendo et al., 2010) 
Class Remark Bacteriocin 
Molecular 
weight         
(amino acids) 
I 
Lanthionine-containing bacteriocins, 
lantibiotics. Includes both single- and two-
peptide lantibiotics 
Nisin A  3,354 (34) 
  Nisin Z  3,331 (34) 
  Nisin Q  3,327 (34) 
  Nisin F  3,317 (34) 
  Lacticin 481  2,901 (27) 
 
 Lacticin 3147  
A1, 3,306 (30)  
A2, 2,847 (29) 
    
    
    
II  
Non-lanthionine-containing bacteriocins. 
Heterogeneous class of small peptides 
  
    
IIa 
 Listeria-active bacteriocins with a consensus 
sequence in the N-terminal of YGNGVXC 
Lactococcin MMFII  4,143 (37) 
    
    
IIb   
Two-peptide bacteriocins Lactococcin G 
α, 4,346 (39)     
β, 4,110 (35) 
 
 Lactococcin MN 
LcnM, 4,325 
(48) LcnN, 
4,377 (47) 
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 Lactococcin Q 
α, 4,260 (39)     
β, 4,018 (35) 
IIc  Cyclic bacteriocins Lactocyclicin Q 6,063 (61) 
IId   Other class II bacteriocins Lactococcin A 5,778 (54) 
  Lactococcin B  5,327 (47) 
  Lactococcin 972  7,381 (66) 
  Lacticin Q  5,926 (53)  
    Lacticin Z 5,971 (53)  
 
Class II bacteriocins 
The class II are small, heat stable, non-lanthionine-containing peptides, not subjected to 
extensive posttranslational modification. Many class II bacteriocins are active in the 
nanomolar range and pore formation is the most common mode of action. Due to their 
amphiphilic helical structure, these bacteriocins can exert an antibacterial activity through 
the insertion in the cytoplasmic membrane of the target cell, thereby promoting 
membrane depolarization and cell death. Cotter et al. (2005) suggested to divide class II 
bacteriocins into three subclasses: subclass IIa (pediocin-like bacteriocins), subclass IIb 
(two-peptide bacteriocins), subclass IIc (circular bacteriocins) and subclass IId, non-
pediocin single peptide linear bacteriocins. Even though up to 8% of wild type L. 
monocytogenes strains appear to be naturally resistant (Collins et al., 2010), the subclass 
IIa show high specificity against L. monocytogenes: Pediocin PA-1 is the only bacteriocin 
produced not only by different species, but also by different genera of LAB (Pediococcus 
spp. and Lactobacillus spp.). Enterocin (a bacteriocin from Enterococcus spp.) is another 
bacteriocin that firstly belonged to class IIa, but several bacteriocins from E. faecalis 
subsequently found and characterized, were classified in more than one class of 
bacteriocin (Balla et al., 2000). Into the class IIb are gathered those bacteriocins whose 
the foundamental characteristic is to be formed by two peptides, such as Lactococcin G 
and Enterocin 1071 (Balla et al., 2000). Since the activity of both units is crucial to exert 
their antimicrobial effect, the encoding genes are located on the same operon and 
expressed simultaneously. Indeed it is common for one or both peptides to lack activity 
when they are assessed separately, while their combination demonstrate an important 
synergic action and a potent activity (Balciunas et al., 2013). The remaining groups of 
class II bacteriocins are subclass IIc, which is characterized by a covalent binding among 
the N and C-terminii resulting in a circular structure, such as Lactocyclicin Q (Sawa et al., 
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2009) and Lactococcin B (Venema et al., 1993). In the subclass IId are grouped lactococcal 
bacteriocin, such as Lacticin Q, which forms particular, very large pores into the 
membranes, inducing high membrane permeabilization without the need of docking 
molecules (Zendo et al., 2010). Resistance to class II bacteriocins has been frequently 
investigated in relation to the mannose-phosphotransferase systems (man-PTS) that is 
the target receptor for subclass IIa. The lack of a component of man-TPS was sufficient to 
determine the resistance for both Leucocin A and Pediocin PA-1, two pediocin-like 
bacteriocins (Collins et al., 2010). 
1.1.2. Application fields 
The research on the antibacterial activity of bacteriocins has been addressing two 
practical applications: a) food production and preservation and b) use in medical and 
veterinary medicine. In food production, only Nisin and Pediocin PA-1 have found 
widespread use (Cotter et al., 2005). They have shown a potential in preservation of 
meat, dairy products, eggs products, beverage, bakery products and fermented 
vegetables. They can be produced in situ from producers cells added instead of traditional 
starter culture, or added in purified or semi-purified form. The presence of bacteriocins in 
milk seems to have no negative impact on human health, because they are degraded by 
the proteolytic enzymes of the stomach, so they don’t have any detrimental effect on the 
intestinal bacterial flora (EFSA, 2005). Moreover, these molecules do not affect dairy 
transformations, rather they could promote technological improvement, for example by 
controlling adventitious non-starter flora (Cotter et al., 2005). 
Even though investigations about LAB bacteriocins have been mainly driven by food 
industry, the non-toxicity conjugated with the activity of these molecules against Gram-
positive human and animal pathogens has led to investigate potential clinical 
applications. With the widespread development of antibiotic resistant strains, the 
importance of alternative antimicrobials is becoming increasingly urgent (Dicks et al., 
2011) and bacteriocin-producing organisms could be considered as important source of 
antimicrobial agents in the medical and veterinary fields (Pieterse and Todorov, 2010). 
1.1.3. Bacteriocins as alternatives in mastitis prevention and therapy 
Bovine mastitis is one of the most significant causes of economic losses for the dairy 
industry, due to reduction of milk quality and production, discarded milk, early culling of 
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cows, drug costs and enhance of labor for farmers (Coelho et al., 2007). The widespread 
of post-dipping adoption and the antibiotic treatment at drying-off has led to a significant 
progress in mastitis control (Gruet et al., 2001). Antibiotics still represent the election 
treatment for mastitis. Nevertheless, the biggest challenge in the modern dairy industry is 
the reduction of the antibiotics use in food production animals (Bradley, 2002): public 
health authorities advise prudent use of antibiotics because they could promote bacterial 
resistance and leave residues in food chain (Coelho et al., 2007). Since starter cultures for 
cheese and yoghurt manufacture are inhibited by these substances (Miles et al., 1992), 
the dairy industry could benefit from the development of safe antimicrobial agents and 
bacteriocins could be an attractive alternatives to antibiotics (Pieterse and Todorov, 
2010). Furthermore, the dramatic increase in organic production still requires an effective 
alternative against mastitis: the dry period remains difficult to manage in the absence of 
antibiotic dry cow therapy, with significantly more new affected quarters (Berry and 
Hillerton, 2000). In addition to improved environmental management and optimal 
nutrition, Bradley (2002) recognizes the pivotal role of the development of new 
therapeutic agents coming from ‘mammary probiotics’ as an area of possible future 
research that may yield novel approaches to the control of bovine mastitis. 
The lantibiotic Nisin was recently assayed in experimental trials and tested as treatment 
of clinical and subclinical mastitis. The papers highlighted the possibility to achieve a cure 
rate similar to antibiotic treatments avoiding milk withdrawal. The use of antibiotics is 
often inadvisable in subclinical mastitis because of the low cure-rate and the withdrawal 
period for milk (Gruet et al., 2001). 
Two nisin-based products namely Mast Out® (intrammary treatment) and Wipe-Out® 
(dairy wipes) were developed by ImmuCell Corporation (Maine, USA) (Cotter et al., 2005). 
Although Mast Out® showed a significant cure rate in an initial field trial and was licensed 
by Pfizer Animal Healt, the product was not made available on the market and no trial 
was further reported. In two recent studies, the efficacy of Nisin in the treatment of 
clinical and subclinical mastitis was compared with that obtained with antibiotic 
administration. Clinical mastitis caused by Staphylococcus aureus or Streptococcus 
agalactiae (Cao et al., 2007) and subclinical mastitis by Staphylococcus aureus, Coagulase-
Negative Staphylococci, Streptococcus agalactiae, Streptococcus dysgalactiae or 
Streptococcus uberis were considered (Wu et al, 2007). Both studies concluded that 
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administration of Nisin was effective in the treatment of mastitis caused by several 
mastitis pathogens in lactating dairy cows. 
Nisin was also tested for its efficacy in a post-dipping formulation: Ambicin® N showed a 
significant reduction of several pathogens in experimentally challenged teat surfaces after 
1 minute exposure to the germicidal formulation. Furthermore the formulation 
containing Nisin showed a lower potential for skin irritation after repeated exposure in 
contrast to 1% iodophore or 5% chlorexidine digluconate (Sears et al., 1992). Using 
bacteriocin-based products would be advantageous because the complete removal at 
milking time is not required, contrarily to chemical products. 
Also Lacticin 3147 produced by Lactococcus lactis subsp lactis was investigated for use as 
antimicrobial agent in a teat sealant formulation. The results demonstrated Lacticin 
efficacy against mastitis pathogens and stability in teat environment (Ryan et al., 1998). 
Moreover, Pieterse et al. (2010) showed the in vitro susceptibility of mastitis pathogens to 
the new bacteriocin macedocin ST91KM added to a sealing formulation. Traditional teat 
seal formulations are recommended during dry period as a prophylactic measure to 
reduce the number of new infections (Berry and Hillerton, 2002). The inert property of 
the seals formulation has no antimicrobial effect and treatment efficacy relies on good 
udder hygiene practices, therefore the addiction of bacteriocins could improve the 
efficacy of teat sealants. 
Antibiotics administration is recommended at drying-off to improve mastitis control 
programs. However prolonged exposure to low levels of antibiotics could stimulate 
antibiotic resistance development, so bacteriocins could replace antibiotics in these 
formulations (Twomey et al., 2000). The protection given by a teat sealant plus Lacticin 
3147 was tested against experimental challenge with Streptococcus agalactiae and the 
results indicated higher percentage of quarters free from infections when treated with 
the bacteriocin-added teat sealant (Ryan et al., 1998). Similar results were observed by 
Twomey et al. (2000) against Staphylococcus aureus, with the conclusion that Lacticin 
concentration was determinant for the teat sealant to be effective against the pathogen.  
In contrast to antibiotics, bacteriocins are considered as safe because they have been 
always present in various foods since ancient times. Furthermore their proteic nature 
ensures the inactivation by enzymes (such as trypsin and pepsin) during the passage 
through the digestive tract, avoiding the destruction of the gastrointestinal tract 
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microbiota. This means that bacteriocins do not remain in the environment, thus they do 
not promote the development of resistance among bacterial strains into the 
environment. In addition, while antibiotics generally need micromolar level for their 
activity, bacteriocins exert their antibacterial effect at nanomolar level. They act 
specifically on target cell membrane through quick pores formation at extremely low 
concentration. This rapid action is one of the reason for which the development of 
resistant strains was not evidenced as problematic in the practical application of these 
molecules (Zendo et al., 2010, Pieterse and Todorov, 2010).). Although resistance could 
become an issue in the future, especially if bacteriocins will be applied in clinical field, it 
should be considered that Nisin has a 50 years of safe usage in food industry and in more 
than 50 countries without the emergence of acquired resistance (Zendo et al., 2010). On 
the other hand, in the last years the interest on the study of the basis for bacteriocin 
resistance has increased. Also, even if no development of resistance has been reported in 
the practical usage, further insights into resistance development allow us to build up 
strategies to minimize the possibility of such happening. The lowest minimum inhibitory 
concentration (MIC) of the bacteriocin should be established, to reduce the amount of 
bacteriocin in treatment products. Due to the risk of resistance development following 
antibiotic treatments, milk with antibiotic residues cannot be sold. To the contrary, 
bacteriocin residues in milk are accepted and no withholding period would be required if 
bacteriocin therapy were used instead of antibiotics, avoiding economic losses due to 
wastage (Pieterse and Todorov, 2010).  
Furthermore the presence of antibiotic residues in milk can affect cheese and yoghurt 
manufacture because LAB used as bacterial starter cultures are inhibited, thus the quality 
of products compromising (Pieterse, 2009). For these reasons, the implementation of 
new antibacterial molecules, which are safe for human consumption and do not affect 
milk transformations, can be recommended in mastitis prevention and therapy (Pieterse 
and Todorov, 2010). 
1.2. Lactic acid bacteria and mammary immune response against pathogens  
As previously described, an effective, non-antibiotic treatments for mastitis could reduce 
the costs of the depletion of milk during therapy and relieve some of the pressure of 
agricultural and veterinary sectors to limit the use of antibiotics. Several alternatives to 
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antibiotics have been explored and proposed, including milking quarters many times at 
day, hydrotherapy, ultrasonic therapy, topically applied liniment, intramammary infusions 
of glucose solution, lysotaphin and Nisin (Klostermann et al., 2008). The use of probiotic 
bacteria has been proposed as a novel approach to prevent and cure several infections in 
humans and animals, especially in vaginal and in the gastrointestinal tracts (Frola et al., 
2012). In particular, LAB with a GRAS status and an inhibitory activity against pathogens 
are still under investigation. Probiotic LAB may exert their beneficial actions through 
different mechanisms such as adhesion to epithelial cells, colonization, biofilm formation, 
production of antagonistic metabolites, competition for nutrients and immune system 
modulation (Beecher et al., 2009). In recent studies, the efficacy of treatments using 
different genera of LAB (Lactobacillus spp and Lactococcus spp.) and the response of 
mammary gland were evaluated. A first study (Klostermann et al., 2008) was performed 
using the best characterized strain of the lactococcal species, Lactococcus lactis DPC 3147 
producer of Lacticin 3147. A live culture of the microorganism was tested for its efficacy 
in the treatment of clinical and subclinical mastitis, demonstrating similar results when 
compared to antibiotic therapy, with the advantage of no cost for milk withdrawal. 
Furthermore, in the first two days after infusion an increase in SCC was noted, due to the 
influx of PMN into the mammary gland, followed by a rapid decrease and the 
achievement of normal levels to a pre-treatment level. These two observations indicate 
the enhancement of local defenses induced by the infusion of Lactococcus lactis and the 
safety of the treatment, since this microorganism is unable to colonized the treated 
quarters. Such alternative treatments, would also be of interest in organic dairy farms 
where the use of antibiotics is restricted or even prohibited. The application of the same 
Lactococcus strain was subsequently used to study the stimulation of mammary immune 
response through the evaluation of cytokine gene expression. Beecher at al. (2009) 
concluded that infusion with live culture of Lactococcus lactis caused a rapid and 
considerable response with the highest expression levels observed for IL-1β and IL-8 
corresponding to peaks in SCC values. A different LAB, belonging to the genus 
Lactobacillus, was under investigation for its characteristics of mastitis pathogen 
inhibition and co-aggregation, and for its ability to adhere to bovine teat canal epithelial 
cells: the inoculation with Lactobacillus perolens CRL 1724 in non-lactating bovine udders 
was performed providing important information for further studies in the development of 
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probiotic products for bovine mastitis prevention (Frola et al., 2012). This histological 
study highlighted the adherence of LAB on the epithelial cells of cistern accompanied with 
a mild inflammation and the absence of morphological modifications, lesions or necrosis 
indicating that no damage occurred after the inoculation (Frola et al., 2013). This novel 
control strategy was proposed against the major pathogen Staphylococcus aureus by 
Bouchard et al. (2013), demonstrating the protective effect of Lactobacillus strains in the 
preventing adhesion and internalization of the pathogen into bovine mammary epithelial 
cells. 
 
2. MAMMARY INNATE IMMUNE DEFENSES 
 
The mammary gland is open to the environment and therefore is subjected to the 
invasion of pathogen microorganisms. For this reason, an effective immune defense play 
a pivotal role in preventing infection establishment (Ganz, 2004). The overall impact of 
mastitis disease on the quality and quantity of milk produced for human consumption has 
provided the impetus to study the mechanisms of mammary immune response and how 
to prevent disease through immune modulation. Innate immunity is a non-specific 
function, quickly activated at the site of infection by numerous stimuli, but not increased 
by repeated exposure to the same agent (Sordillo and Streicher, 2002). This immune 
reaction is mediated by physical barrier of the teat end, macrophages, neutrophils, 
natural killer cells and certain soluble factors. If non-specific defense mechanisms work 
adequately, most of the pathogens are eliminated within a short period of time and 
before the activation of the specific immune response. To the contrary, the acquired 
immune system is activated when pathogens evaded the innate defense or is not 
completely eliminated: the recognition of specific pathogen antigens results in an 
immunological memory which provides a faster and a stronger response in clearing the 
pathogen. The innate immune response is mediated by macrophages, lymphoid 
populations and immunoglobulins. In the mammary gland both innate and acquired 
immunity are required in order to provide an optimal defense from mastitis, but here we 
consider only innate immunity, since it is the predominant protection of the mammary 
gland during the first stage of infection (Bannerman, 2009). 
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2.1. Anatomical defenses 
The teat canal is the first line of defence against mastitis, since this is the route by which 
invading pathogens can gain entrance to the mammary gland. In the distal part of the teat 
sphincter muscle maintains tight closure between milkings and hinders bacterial 
penetration. Increased opening of the sphincter is directly correlated to increased 
incidence of mastitis (Rainard et al., 2005). 
This canal is locked between milkings and in the dry period by a keratin plug derived from 
the stratified epithelial lining. The role of the plug is creating a physical barrier preventing 
the penetration of bacteria in the gland cistern. Indeed, keratin is able to bind and 
immobilized most strains of non-encapsulated mastitis-causing bacteria (Rainard et al. 
2005). Some components of keratin have antimicrobial activity: esterified and not 
esterified fatty acids, such as myristic acid, palmitoleic acid and linoleic acid, are 
bacteriostatic. Furthermore, keratin cationic proteins can bind electrostatically to the 
mastitis-causing bacteria, altering their cell wall and affecting their resistance to osmotic 
pressure (Hogan et al., 1987). The bactericidal efficiency of keratin may be limited by 
different factors, above all inadequate milking procedures. Close to the parturition, a high 
accumulation of fluid occurs within the udder, , causing increased intramammary 
pressure. Thus, the leakage of mammary secretions and dilatation of the teat canal 
increase susceptibility to mammary infections (Sordillo and Streicher, 2002). 
 
2.2. Soluble defenses  
Cytokines 
This group of small soluble proteins (less than 50kDa) has a crucial role in cell signalling, in 
the mammary gland they provide the balance between humoral and cell-based immune 
responses. Although cytokines play an essential role in the host response to infection, 
they can have deleterious effects. Thus, there is a fine balance between the positive and 
negative effects of cytokines on the host that is dictated by the duration, amount, and 
location of their expression (Bannerman, 2009). Some cytokines clearly promote 
inflammation, while others suppress the production of inflammatory mediators. They 
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comprise interleukins (IL), chemokines, interferons (IFN), tumor necrosis factors (TNF) and 
colony stimulating factors (CSF) (table 1). 
 
Pro-inflammatory cytokines 
Tumor necrosis factor- 
Tumor necrosis factor- (TNF) is produced very early in inflammation stimulating 
the acute phase reaction. TNFα is an essential mediator of inflammation because 
in combination with IL-1 it triggers changes in the vascular endothelial cells that 
line small blood vessels. A local increase in TNFα causes the classic signs of 
inflammation, including heat, swelling, pain, and redness The massive 
inflammatory response observed during coliform mastitis is accompanied by 
elevation of TNF levels causing such severe symptoms. In coliform mastitis, TNF 
induces plasma haptoglobin, promotes recruitment and activation of neutrophils 
and raises intra-mammary and systemic nitrite and nitrate (Tizard, 2013). In 
contrast to the continuous and sustained release of TNF in coliform mastitis, in S. 
aureus infected glands, TNF transcriptional activity has only a short episodic 
elevation at 24 h post infection (Alluwaimi, 2004), sustaining the 
immunosuppressive nature of S. aureus infections (Allowaimi et al., 2003). To the 
contrary, in vitro studies using bMEC, showed a significant increment of TNF one 
hour after S. aureus experimental challenge, demonstrating the increase of 
cytokine production in the early phase of infection (Griesbeck-Zilch et al., 2008). 
Despite this early increment, S. aureus challenge results overall in lower 
production of TNF if compared with E. coli. These results can explain the 
undetectable level of TNF in mastitic milk during the in-vivo S. aureus challenge 
(Lahouassa et al., 2007). Despite its pro-inflammatory activity, TNF has been 
detected not only in infected bovine mammary gland but also in normal quarters 
during periparturient period, lactation and involution, demonstrating its essential 
role in regulating and maintaining immunological function during physiological 
changes of mammary gland (Alluwaimi, 2004). 
 
 
21 
 
Interleukin-1 
Interleukin-1 (IL-1) includes the secreted IL-1 and the cytoplasmatic IL-1; 10- to 
50-fold more IL-1β is produced than IL-1α. They are produced by macrophages 
and epithelial cells and are mediator of local and systemic immune response: it 
can regulate cells proliferation and apoptosis, and the expression of other 
cytokines, acute phase proteins and enzymes for the eicosanoid synthesis 
(Schukken et al. 2011). During severe infections, IL-1β circulates in the 
bloodstream where, in association with TNF-α, it is responsible for sickness 
behaviour (Tizard, 2013) and signs of acute septic shock (Ohtsuka et al., 2001). 
Due to the influx of neutrophils in association with the increase in IL-1 level 
observed in E. coli mastitis, it has been postulated that IL-1 is indirectly involved in 
chemo-attraction of neutrophils (Schuster et al. 1997). To the contrary, in S. 
aureus mastitis the role of IL-1 is negligible or transient, indicating the minor role 
in S. aureus mastitis (Riollet et al., 2001). Despite its pro-inflammatory nature, the 
immunotherapeutic properties of IL-1 have been investigated: IL-1 has been 
proposed as adjuvant in the S. aureus mastitis, demonstrating its efficacy in 
neutrophils influx enhancement, in the oxygen radical upregulation and in the 
increase of intracellular potency of some antibiotics (Alluwaimi, 2004). 
Interleukin-6 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine with additional anti-
inflammatory properties. It promotes some aspects of inflammation, especially in 
response to tissue damage and severe infections, since it is a major mediator of 
acute-phase reaction and of septic shock (Tizard, 2013). Macrophages, T 
lymphocytes and epithelial cells produce IL-6 (Okada et al., 1997). In the 
mammary gland IL-6 regulates the acute phase protein synthesis and promotes a 
shift from neutrophils to monocytes influx, essential to prevent the detrimental 
effect of neutrophils allowing a suitable immune response (Allowaimi, 2004). It is 
expressed both in infected mammary glands and in healthy ones. Hagiwara et al. 
(2001), in an in vivo study of naturally infected cows, observed the highest 
concentration of IL-6 during E. coli mastitis, when compared with other 
pathogens. In contrast to its active presence in coliform mastitis IL-6 activity was 
confirmed to be negligible in S. aureus infection (Alluwaimi et al., 2003). 
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Chemokines 
Chemokines are a family of at least 50 small (8 to 10-kDa) chemotactic cytokines. 
They coordinate the migration of cells and hence dictate the course of many 
inflammatory and immune responses. Chemokines act predominantly on 
macrophages and dendritic cells (Tizard, 2013). 
Interleukin-2  
Interleukin-2 (IL-2) is produced mainly by T-lymphocyte, it is involved in the 
growth and activation of B-lymphocytes, activation of NK cells and induction of 
cytotoxic T-cells activation. Bovine IL-2 has been detected in epithelial cells of 
both normal and mastitic mammary gland (Alluwaimi, 2004). It has been 
demonstrated that decreased IL-2 endogenous production contributes to reduce 
immune capabilities, with the consequent development of disease. In some 
studies, a correlation between low amount of IL-2 in colostrums and increased 
susceptibility to mastitis was observed and the possibility to enhance mammary 
gland defences with IL-2 has received considerable attention (Sordillo and 
Streicher, 2002). IL-2 was investigated for its therapeutic use in the treatment of S. 
aureus mastitis. The infusion of IL-2 in infected quarters caused a significant 
immunopotentiation by overwhelming recruitment of lymphocytes, neutrophils, 
macrophages and eosinophils (Alluwaimi, 2003). Nevertheless, apparent enhanced 
immunomodulation in the IL-2 infused normal and/or mastitic mammary glands 
did not result in prevention or cure of the infection (Alluwaimi, 2004). 
Interleukin-8 
Interleukin-8 (IL-8) is produced by macrophages, monocytes, mast cells, T-
lymphocytes, as well as epithelial and endothelial cells. It has the function to 
attract and activate neutrophils, stimulating their respiratory burst and the release 
of their granule contents (Tizard, 2013). In the mammary gland IL-8 plays a crucial 
role in neutrophil recruitment (Sordillo and Streicher, 2002). Barber and Yang 
(1998), demonstrated the biological role of IL-8 in attracting neutrophils into 
infected bovine udder, showing lower neutrophil chemotactic activity in the 
presence of anti-IL-8 antibodies in mastitic mammary secretion. The main source 
of IL-8 in udder has been further investigated by measuring its level in milk and in 
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lymph from afferent and efferent lymphatic vessels of the supra-mammary lymph 
node. The level of IL-8 was higher in milk than in lymph, indicating that mammary 
epithelium rather than sub-epithelial tissue is a major source of the cytokyne 
(Waller et al., 2003). Mammary epithelial cell lines stimulated with LPS, IL-1, S. 
aureus and/or E. coli showed a copious production of IL-8 (Alluwaimi, 2004). IL-8 is 
actively produced in E. coli mastitis, whereas it is present in lower concentration in 
mastitis caused by S. aureus both in in vitro (Griesbeck-Zilch et al., 2008) and in in 
vivo studies (Bannerman et al., 2004). The increase of IL-8 concentration is 
associated with higher somatic cell count, highlighting the crucial role of IL-8 in the 
recruitment of leukocytes into the mammary gland, which is essential for the 
elimination of invading pathogens. Furthermore, in contrast to the more transient 
effects of other chemoattractants, IL-8 is able to exert a longer lasting effect, 
presumably because of its resistance to proteolytic degradation and slower 
clearance from tissues (Bannerman, 2009).  
 
Anti-inflammatory cytokines 
Interleukin 10 
Interleukin-10 (IL-10) is one of the best characterized anti-inflammatory 
interleukins in udder immune response. IL-10 has two main functions, the 
inhibition of cytokine synthesis and the reduction of factors of the MHC-II complex 
(Schukken et al. 2011). A significant increase in the amount of IL-10 in milk after 
infection with E. coli was observed, while S. uberis infection showed a delayed 
response (Bannerman, 2009). Natural S. aureus infected quarters showed a 
limited IL-10 response (Bannerman et al., 2004), but IL-10 had been previously 
detected in milk somatic cells from chronic infected quarters, supporting the 
lower inflammatory status that characterized S. aureus chronic mastitis (Riollet et 
al., 2001). Interestingly, IL-10 secretion is subsequent to TNF increasing, but 
differently to what observed for TNF, the response seems not to be related to 
the bacterial cell wall type. For instance, S. uberis has been shown to evoke milk 
IL-10 concentrations similar to E. coli. However increases in IL-10 production are 
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detected earlier in response to gram-negative bacteria than to gram-positive or 
wall-less bacteria, similarly to TNF (Bannerman, 2009). 
Interleukin 12 
Interleukin-12 (IL-12) is a key cytokine that determines Th1/Th2 polarization. IL-12 
is produced by macrophages, dendritic cells, B cells, and neutrophils (Tizard, 
2013). Similarly to IFN-γ, IL-12 acts to link the innate and adaptive arms of the 
immune system, and plays an essential role in modulating the host immune 
response to bacterial and parasitic intracellular pathogens (Bannerman, 2009). In 
mammary cells isolated from cows experimentally infected with E. coli or S. aureus 
an increase in IL-12 mRNA was detected (Alluwaimi et al., 2003), as well as in 
naturally occurred S. aureus mastitis (Riollet et al., 2001). 
Interferon-γ 
Interferon-γ(IFN-γ) plays a key role in the immunity against intracellular pathogens 
and is the most extensively studied interferon in udder immunity (Schukken et al. 
2011). Increasing abundance of IFN-γ mRNAs was detected in milk cells as well as 
increasing protein amounts in milk isolated in the course of mastitis (Bannerman, 
2009; Riollet et al., 2001). Cellular sources of IFN-γ include lymphocytes, natural 
killer cells, and cells of monocyte lineage. The influence of IFN-γ on the innate 
immune system is most evident from its effects on macrophages and neutrophils. 
IFN-γ enhances the microbial activity of these cells by increasing receptor-
mediated phagocytosis, inducing respiratory burst activity, and priming nitric 
oxide production (Bannerman, 2009). Furthermore, IFN-γ links innate with 
acquired immunity inducing the production of IL-12 (Alluwaimi, 2004). 
Complement system 
The complement system is is a set of proteins that help the lysis of bacteria through pore-
formation, the opsonization and attraction of phagocytes, after a cascade of events, in 
which each step leads to the next. The components of complement complex are 
synthetized mainly by epathocytes but also by monocytes and tissue macrophages 
(Sordillo and Streicher, 2002). In milk, the highest concentrations of complement complex 
proteins (C) were observed for colostrum, mastitic milk and in the mammary secretions 
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during involution, while they were lower in healthy glands during lactation (Sordillo and 
Streicher, 2002). Although the overall function of complement system in mammary gland 
defence has yet to be fully determined, available knowledge supports its predominant 
pro-inflammatory role in intramammary infections (Riollet et al., 2000; Bannerman, 
2009). It has been postulated that the classical pathway of complement activation is 
impossible in milk from healthy quarters due to the lack of the component C1q (Reinard 
et al., 2003). Nevertheless the alternative pathway can operate with a double outcome: 
deposition of opsonic C3b and iC3b on bacteria, and generation of the pro-inflammatory 
fragment C5a. The C5a fragment is among the most potent chemoattractants for 
neutrophils and for cells of monocytic lineage inducing the migration of these cell types 
through the mammary epithelium. The fragment C5a is also a potent stimulator of the 
phagocytic function and respiratory burst activity of neutrophils (Alluwaimi, 2004). 
N-acetil-β-D-glucosaminidase and Lysozyme  
During mastitis, while the enzymes related with the synthesis of milk decrease, the 
enzymes associated to inflammation increase, such as N-acetil-β-D-glucosaminidase 
(NAGase; Pyörälä, 2003) and Lysozyme (LZ; Osman et al., 2010). They are lysosomal 
enzymes, considered as reliable indicators of inflammation (Pyörälä, 2003).  
NAGase is mainly released from the polymorphonuclear leucocytes during phagocytosis 
and cell lysis (Åkerstedt et al., 2011) and to some degree from damaged epithelial cells. It 
plays a role in mammary gland immune response (Torben and Karen, 2012) and its 
amount in the milk is related to pathogen strain (Kitchen et al., 1981; Ebling et al., 2001). 
The enzyme activity in milk was shown to increase in subclinical mastitis (Åkerstedt et al., 
2011). NAGase activity was also found in clinically healthy cows (Åkerstedt et al., 2011) 
with the highest levels in the first 20 days post-parturition, followed by a decline and a 
stabilization after 160 days of lactation (Piccinini et al., 2007). Despite the increase of this 
enzyme in mastitic milk, in the absence of inflammation the inconsistency between 
somatic cell count mean values and NAGase activity suggests that tissue factors may 
contribute to the release of some immune components (Piccinini et al., 2007). Recently, 
mammary epithelial cells of a continuous cell line, BME-UV1, were shown to produce 
NAGase when infected with S. aureus strains, as well as in the absence of stimuli (Mazzilli 
and Zecconi, 2010). NAGase distribution in a variety of tissue and in extracellular 
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compartments has led some studies to investigate the suitability of this enzyme as a 
marker of tissue damage. Recent studies demonstrated a correlation between high level 
of extracellular NAGase and tubular damage: Forman et al. (1996) published the first 
paper regarding NAGase in the urinary excretion of hens, concluding that this enzyme 
could be successfully used as a marker of kidney damage in hens. Later, Sato et al. (2002) 
showed the clinical usefulness of measuring NAGase in urinary tract diseases of cats. 
While NAGase is considered a marker of inflammation and tissue damage, LZ, with its 
antibacterial properties, is an indicator of mammary gland immune response. 
LZ is one of the most extensively studied antibacterial milk proteins. It has a well-
recognized bactericidal effect against both Gram-positive and Gram-negative bacteria 
(Lopez et al., 2006) and represents one of the components of mammary gland innate 
immune defenses, fundamental in preventing pathogen invasion. Indeed, together with 
lactoferrin, LZ is one of the most abundant proteins contained in neutrophils-specific 
granules (Ganz, 2004). It plays an antibacterial activity killing ingested bacteria in the 
phagolysosomes and preventing colonization through exocytosis of polymorphonuclear 
leucocytes secondary granules (Zecconi and Smith, 2003). The mode of action of LZ is not 
yet completely understood: while it is well known for its catalytic function related to the 
damage of bacterial cell walls (it cleaves the bond between N-acetyl muraminic acid and 
N-acetyl glucosamine and destroys cell wall peptidoglycans in Gram-positive bacteria; 
Tizard, 2013), a non-enzymatic mechanism exhibiting antibacterial activity against Gram-
negative microorganisms has been proposed (Ibrahim et al., 1996). As a matter of fact, LZ 
is highly active against many Gram-positive species but it can synergize with antibodies, 
complement or lactoferrin, allowing the disruption of the outer membrane of Gram-
negative bacteria and the access to peptidoglycan (Ganz, 2004). Due to a small 
concentration of IgA in ruminant milk and to a low amount of LZ, it is unknown if this 
mechanism is active in the bovine mammary gland (Sordillo and Streicher, 2002). 
Furthermore, a recent study provides a different mode of action of LZ, demonstrating the 
antimicrobial activity of LZ-deriving peptides. These peptides, isolated from proteolytic 
digests of hen egg white LZ, were internalized in both E. coli and S. aureus after the 
interaction with membrane phospholipids. These internalized peptides did not only affect 
the membrane permeability, but affected intracellular functions (Hunter et al., 2005). As 
for NAGase, LZ was secreted in the milk also in the absence of inflammatory reaction. 
27 
 
Furthermore the higher levels of enzyme in latent infections in comparison with 
subclinical and healthy mammary quarters, showed a role of this molecule in the control 
of invading pathogens (Piccinini et al., 2007). 
Lactoferrin 
Lactoferrin (Lf) is an iron-binding protein produced by leukocytes and epithelial cells. It is 
first known for its iron-chelating functions, which are the basis of two activities: a non-
specific bacteriostatic activity and protection against oxygen radicals. These properties 
depend on Lf capability to bind free ferric ion in milk, avoiding the growth of iron-
depending bacteria and blocking the reactions of free radicals, which are catalysed by 
free iron. On the other hand, bovine mammary epithelial cells secrete citrate in milk and 
this secretion creates an ideal buffer that chelates iron and makes it available to bacteria, 
abolishing the bacteriostatic activity of lactoferrin (Sordillo and Streicher, 2002). Bovine 
milk contains small amount of Lf (20-200 µg/mL) in comparison to bovine colostrum (2-5 
mg/mL) and to the secretions of non-lactating mammary gland, which can contain very 
high concentration of Lf (20-100 mg/mL). Thus, the secretion of Lf is inversely related to 
alveolar development and Lf bacteriostatic and bactericidal activities are likely to be more 
important when the mammary gland is fully involuted (Molenaar et al. 1996). 
Transferrin  
Transferrin (Tf) is similar to lactoferrin for its iron-binding functions, and is found in milk. 
This protein comes from blood, by transcytosis in the normal gland and through 
exudation of plasma during mastitis. Bovine milk contains low amounts of transferrin (20-
40 µg /mL); higher amounts are present in colostrum (1mg/mL), but the highest Tf 
amounts are in the blood (4-5mg/mL). Transferrin may allow a first iron-chelating 
bacteriostatic effect, before the increase of Lf concentration (Alluwaimi, 2004). 
Xanthine oxidase 
This enzyme is located in the membrane of milk fat globules. It catalyses the formation of 
nitric oxide from inorganic nitrite, which under aerobic condition leads to generation of 
peroxynitrite, a powerful bactericidal agent (Alluwaimi, 2004). 
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Antibodies 
“Natural” antibodies circulate in normal healthy individuals without the need of antigenic 
stimulation: they are mostly the IgM antibody isotype (Boes, 2000). Two types are 
distinguished, the one directed against exogenous antigens and the other against self-
antigens (Baumgarth et al., 2005). IgM are polyreactive and mostly directed against 
bacterial antigens, such as lipopolysaccharide, lipoteichoic acid and peptidoglycan and 
opsonize efficiently S. aureus and E. coli in rather low concentrations (less than 1%; Wijga 
et al., 2013). They are components of innate immunity and can cooperate with 
complement system in the first line of defence. Van Knegsel et al. (2007) suggested that 
concentration of IgM in both plasma and milk of dairy cows in early lactation was 
negatively influenced by compromised metabolic health in the periparturient period with 
consequent reduce immune functions. 
The primary isotype found in healthy mammary secretion are IgG, produced by antigen-
activated B lymphocytes and components of specific immune response. Togheter with 
IgG, IgM act opsonising bacteria and thus enhancing the phagocitic activity of neutrophils 
and macrophages (Sordillo and Streicher, 2002). 
 
2.3. Cellular defenses 
Leucocytes are the most representative cells of innate immunity of the mammary gland, 
including neutrophils, macrophages and lymphocytes. Other cell types such as dendritic 
cells and mammary epithelial cells should be added as components of milk somatic cells 
(SC). Mammary epiyhelial cells (MEC) are the interface between udder and invading 
microorganisms, thus they have a crucial role for an efficient immune response. Even 
though the amount of MEC depend on the lactation phase, milk from healthy bovine 
mammary gland contains a small number of epithelial cells and leukocytes. Recently a 
count of somatic cells (SCC) of 100.000 cells/mL was suggested in absence of 
inflammation (Hillerton, 1999). Lactation stage affects the SCC so that immediately after 
parturition SCC is high, but , but in healthy quarters decrease within 3 days after calving 
(Barkema et al., 1999). Towards the end of the lactation period, SCC increases slightly 
until drying-off, when udder tissues undergoes several physiological changes. 
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Nevertheless, according to more recent studies, the physiological effects affect very little 
the SCC of truly healthy cows (Leavens et al., 1997). 
Neutrophils are non specific leukocytes that are recruited actively in the infection site. 
While they are in low number in the healthy mammary gland, they increase to 90% of 
total mammary cell population in mastitic quarter milk (Sordillo and Streicher, 2002). 
During infection, the neutrophils are recruited by chemotactic stimuli from blood into 
the milk and they play an efficient phagocytosis and killing of pathogens (Schukken et 
al., 2011), exploiting their crucial role in the elimination of invading bacteria. 
Macrophages represent the major cell type in the secretion of involuted udder and in 
the tissues of a healthy mammary gland, but not in the milk (Pilla et al., 2013). The 
nonspecific function of these cells is to phagocytise bacteria and destroy them with 
proteases and reactive oxygen species. The phagocyte activity of these cells is lower if 
compared with neutrophils, but it can increase in the presence of opsonic antibodies 
against particular pathogens. Furthermore, they can secrete substances that promote 
both migration and bactericidal activity of neutrophils. Indeed, activated 
macrophages are triggered to release prostaglandins, leukotrienes, and cytokines that 
can augment local inflammatory processes. Therefore, the ability of macrophages to 
secrete substances that mediate the migration and bactericidal activity of neutrophils 
is considered of higher importance to the non-specific mammary gland defense, than 
their phagocytic activity. Macrophages also play a role in the development of specific 
immune response, through antigen processing and presentation (Sordillo and 
Streicher, 2002). 
Lymphocytes are able to recognize antigens through specific membrane receptors, 
which give the immunological characteristics of specificity, diversity, memory, and 
self/non-self recognition. In healthy mammary gland T lymphocytes represent the 
major lymphocyte subset, including CD4+ (T helper) and CD8+ (T cytotoxic or T 
suppressor) lymphocytes. Even though the specific leukocyte populations mediating 
the immune response during IMI are not well defined (Schukken et al., 2011), it is 
known that lymphocyte subset which prevail after staphylococcal infections is CD4+ T 
cells, while with streptococcal mastitis there is a parallel increase in both CD4+ and 
CD8+ T-cells (Sordillo, 2005). Mehrzad et al. (2008) studied the T-cell dynamics after 
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an experimental E. coli challenge infection. They observed there was a significant 
decline in the CD4+/CD8+ ratio at 6–24 h after challenge due to greater CD8+ cell 
concentrations in milk. CD8+ T lymphocytes has a scavenger activity, eliminating old 
or damaged secretory cells (Schukken at al., 2011). Furthermore, they are thought to 
modulate immune response during bacterial infections through their suppressor 
function. This phenomenon is dependent on stage of lactation and is observed in 
particular in the early stage of lactation (Sordillo and Streicher, 2002). The primary 
role of B lymphocytes is to produce antibodies against pathogens. They use specific 
surface receptor molecules to recognise specific antigens and similarly to 
macrophages and dendritic cells they function also as antigen-presenting cells. 
Natural killer (NK) cells are a lymphocyte subpopulation with an antibody-dependent 
cytotoxic activity, which is independent from MHC. NK cells are capable to eliminate 
tumoral and virus-infected cells, but NK cells has also potent bactericidal activity 
against both Gram+ and Gram- bacteria (Sordillo and Streicher, 2002). 
Bovine mammary epithelial cells (bMEC) have shown to be highly immune competent 
(Strandberg et al., 2005; Lahouassa et al., 2007; Gunther et al., 2010). bMEC are able 
to release a variety of inflammatory mediators such as cytokines, antimicrobial 
peptides, and arachidonic acid metabolites. The role of these messenger molecules is 
not completely understood, but they may be involved in the recruitment of 
neutrophils and lymphocytes into milk (Günther et al., 2010). The epithelial cells have 
both a sentinel and an effector role and they are well suited to exert these functions 
due to their abundance and exposed position to invading microorganisms (Günther et 
al., 2010). A burst of cytokines synthesis follows the contact between bMEC and 
pathogens: the reaction is stronger after E. coli challenge in comparison with S. aureus 
experimental infection (Günther et al., 2010). These cells are the first to come in 
contact with invading pathogens, thus activation of immune response of bMEC is 
involved in the evolution of infection. In vitro studies using a continuous cell line 
(MAC-T) showed that the cells secreted IL-8 under stimulation with LPS, in a time and 
dose-dependent manner (Boudjellab et al., 1998). Analogously, primary cultures of 
bMEC showed enhanced expression of chemokines, when stimulated by LPS 
(Strandberg et al., 2005). The secretion of pro-inflammatory cytokines by bMEC has 
been investigated after S. aureus challenge, with different results, however TNFα was 
31 
 
secreted after stimulation in all of the studies (Wellnitz et al., 2004; Strandberg et al., 
2005, Lahouassa et al., 2007). In the latter study, IL-1β and IL-8 increased, but less 
than in E. coli bMEC infection. To the contrary, the two major anti-inflammatory 
cytokines IL-10 and TGF-β were not affected by the presence of both pathogens, 
indicating that bMEC are not the source of the high IL-10 levels observed during cronic 
S.aureus mastitis that is characterised by moderate inflammatory response 
(Lahouassa et al., 2007). 
 
3. IN VITRO STUDY OF BOVINE MAMMARY GLAND 
 
In vitro models provide a useful system for the analysis of bovine mammary gland 
response. They take advantage from the growth of udder secretory cells in a controlled 
environment, in relatively short time and at low costs. 
In recent years, considerable progress has been made in understanding the molecular 
mechanisms driving the different functions of the ruminant mammary gland and in-vitro 
experimental models based on mammary epithelial cells culture have been applied for 
this proposal (Matitashvili et al., 1997). These models are currently used to investigate 
the mechanisms involved in milk production, cellular proliferation and differentiation, or 
to study mammary gland metabolisms or again the interactions between mammary tissue 
and pathogens and/or their products (Matitashvili et al., 1997). Nowadays two 
immortalized cell lines derived from bovine mammary epithelium are available: MAC-T 
cells and BME-UV1 cells (Zhao et al., 2010). 
BME-UV1 are established from primary bovine mammary epithelial cells by stable 
transfection with a plasmid encoding the SV40 large T-antigen, a viral oncogene that 
prevent the senescence upon continuous passage and not affects metabolic activity. 
BME-UV1 cells are able to synthesize -lactoalbumin ands1-casein (Zavizion et al., 
1994). Moreover they are the only known bovine mammary epithelial cell line showing 
enhanced proliferation in the presence of epidermal growth factor (EGF) (Zavizion et al., 
1996). Based on these characteristics this continuous cell line has been used as a valid 
model for the investigations on bovine mammary epithelium. In comparison with primary 
cell cultures, the established ones show a reduced possibility of alteration of their original 
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characteristics caused by genetic drift, which is the major limitation of primary cultures 
(Matitashvili et al., 1997). Furthermore the researcher can avoid both the biological 
variability associated with the natural differences between individual organisms and some 
of the complexity inherent for freshly isolated cells, which may contain cells at different 
stages of differentiation. Additionally, immortalized cells are available at different 
passages and the use of the same cell lines in different laboratories makes the results 
more comparable (Matitashvili et al., 1997). BME-UV1 cells express immunological and 
inflammatory molecules (Mazzilli and Zecconi, 2010) and therefore can be successfully 
applied to test the interactions of mammary gland epithelial cells with bacteria and 
antimicrobials (Didier and Kessel, 2004; Fitzgerald et al. 2007). 
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AIM OF THE STUDY 
 
The use of antibiotics for prophylactic treatment is being subjected to considerable 
debate all over the world for its connection with the emergence of antimicrobial 
resistance in pathogens (Frola et al., 2013). Moreover, the use of antibiotic treatment 
during lactation causes the presence of antibiotic residues in milk. For these reasons a 
pressure for the reduction of the use of antibiotics in veterinary field is ongoing, and the 
researchers are interested in finding novel molecules and in the development of new 
alternative approaches. The current use of lactic acid bacteria (LAB) as probiotic cultures 
and their ability to produce antimicrobial molecules encourage investigations of the 
employment of their bacteriocins or viable cell cultures into the mammary gland with the 
subsequent in situ production of antimicrobial molecules. In recent studies, the efficacy of 
treatments using different genera of LAB or their antibacterial products was evaluated 
(Frola et al., 2012;  Wu et al., 2007; Cao et al., 2007). Furthermore, there is the evidence 
that some probiotics can stimulate a protective immune response enhancing resistance to 
invading pathogens (Klostermann et al., 2008; Beecher et al., 2009). However, the 
information regarding this subject is still scarce. Either, the antimicrobial proteins 
(bacteriocins) or viable bacteriocin-producing Lactococcus spp. cultures, applied into the 
mammary gland come in contact with both invading pathogens and epithelial cells, which 
are involved in the activation of immune response and thus in the evolution of infections. 
The stabilized line of bovine mammary epithelial cells (BME-UV1) produces 
proinflammatory cytokines upon stimulation with antimicrobial peptides (Tomasinsig et 
al., 2010). Therefore, it is a suitable in vitro model to assess the response of bovine 
mammary epithelial tissue to bacteriocins and to evaluate the interaction between 
epithelial cells and viable Lactococcus spp. cultures. 
The aim of the present study was to evaluate the potential use of LAB bacteriocins against 
mastitis pathogens and the role of both LAB live cultures and their bacteriocins in 
modulating the response of mammary epithelial cells. 
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Most specifically, the tasks were: 
1. To set up the optimal culture conditions for improvement of the growth of LAB 
and for optimization of bacteriocin production and extraction. 
2. To establish the best antibacterial assays to screen large numbers of producer 
strains. 
3. To evaluate the bacteriocin efficacy against mastitis pathogens. 
4. To characterize the antibacterial proteins in the extracts of selected LAB 
producers. 
5. To assess the immune response of mammary epithelial cells to the challenge with 
both antibacterial extracts and live producer bacterial strains. 
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MATERIALS AND METHODS 
 
1. SCREENING OF LAB STRAINS 
1.1. Preparation of cell-free culture supernatants 
Overall 65 strains of LAB come from Centro Sperimentale del Latte (CSL, Zelo Buon 
Persico, Lodi) collection were tested: Lactococcus lactis subsp. lactis (25 strains), 
Lactococcus lactis subsp. cremoris (16 strains), Lactococcus lactis subsp. lactis bv. 
diacetylactis (11 strains), Lactobacillus plantarum (one strain), Lactobacillus rhamnosus (2 
strains) Lactobacillus paracasei (one strain), Lactobacillus acidophilus (2 strains), 
Lactobacillus fermentum (one strain), Lactobacillus helveticus (4 strains), Lactobacillus 
rheuteri (one strain) and Bifidobacterium spp. (one strain). 
Six different media were used to grow Lactococcus lactis subsp. lactis (LL11), in order to 
investigate which medium could allow the highest antibacterial activity: TGE1 (1% 
Tripticase, 1% Glucose, 1% Yeast extract), TGE2 (TGE broth additioned with 0,5% sodium 
citrate, 0,1% sodium acetate and 0,05% dipotassium phosphate, Yang et al., 1992), GYB1 
(1% Glucose, 0,5% Yeats extract), GYB2 (2% Glucose, 1% Yeast extract), SG (3% milk whey, 
1% glucose), MRS (DeMan, Rogosa, Sharpe broth; Oxoid, UK). One colony of a 24h-culture 
was picked from MRS plate and inoculated in 15 mL of each medium. After 18h 
incubation at 30°C, the culture broth was plated on MRS agar (DifcoTM) and counted, 
while the cell-free supernatants (CFS) were tested with spot-on-lawn assay  and MIC test 
against S. agalactiae MB386 (see below). 
Cell-free supernatants (CFS) of all screened strains were obtained directly from the 
cultures in deMan, Rogosa and Sharpe broth (MRS), by acid extraction method following a 
previously described protocol (Yang et al., 1992). Briefly, after incubation for 18-24 h at 
30°C for Lactococcus spp. or at 37°C for Lactobacillus spp., culture broths were acidified at 
pH 2. After the release of bacteriocins, the broths were centrifuged at 29.000 x g for 15 
min and adjusted to pH 7. Finally CFSs were sterilized by filtration through 0,22 µm filter 
and stored at -20°C until use. 
1.2. Antimicrobial activity test: spot-on-lawn assay 
Antibacterial activity of supernatants was screened with the spot-on-lawn assay 
(Saavendra et Sesma, 2011). All LAB supernatants extracted with the method described 
above from all strains of LAB were tested. LAB strains were maintained on MRS agar at 
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4°C until use. For this test Brain Heart Infusion (BHI) agar plates supplemented with 5% of 
Foetal Calf Serum (FCS) were applied. S. agalactiae MB386 was used as indicator strain 
for CFS activity. A suspension containing 106 UFC/mL S. agalactiae MB386 was prepared 
and spread onto the plate surface. Five µL of each LAB CFS was spotted on the plate and 
then incubated at 37°C for 18-24h. The presence of a clear zone of growth inhibition 
indicated bacteriocin activity. 
 
2. ANTIBACTERIAL ACTIVITY AGAINST MASTITIS PATHOGENS  
2.1. Bacterial strains 
Antibacterial activity of bacteriocin-producing strains was tested against six different 
species of mastitis pathogens, including methicillin resistant strains of Staphylococcus 
aureus.  Except for one S. aureus strain obtained from American Type Culture Collection 
(ATCC, Manassas, VI, USA) all bacterial strains had been isolated from clinical and 
subclinical mastitis. All tested strains are listed in the table 1. 
 
Table 1. Bacterial strains used in the antimicrobial activity tests and their origin. 
 Species Strain Source 
Streptococcus agalactiae MB90 mastitic milk 
 MB98 mastitic milk 
 MB386 subclinical mastitis 
Streptococcus uberis MB705 clinical mastitis 
 MB707 post-treatment mastitis 
 MB300 subclinical mastitis 
Streptococcus dysgalactiae MB280 mastitic milk 
 MB324 subclinical mastitis 
Enterococcus faecalis MB330 subclinical mastitis 
 MB561 subclinical mastitis 
 MB562 subclinical mastitis 
 MB706 subclinical mastitis 
Staphylococcus aureus 29213 ATCC 29213 
 MB221 subclinical mastitis 
 MB254 subclinical mastitis 
 MB351 subclinical mastitis 
 MB390 subclinical mastitis 
 MB439 subclinical mastitis 
 MB501 subclinical mastitis 
 MB512 subclinical mastitis 
 MB535 clinical mastitis 
 MB543 subclinical mastitis 
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 MB781 subclinical mastitis 
 MB786 subclinical mastitis 
 MB798 clinical mastitis 
Methicillin-resistant Staphylococcus aureus 
(MRSA) 
MB508 subclinical mastitis 
 MB628 subclinical mastitis 
Coagulase-negative staphylococci (CNS) 
MB307 subclinical mastitis 
 MB309 subclinical mastitis 
  MB316 subclinical mastitis 
 
 
For bacteriological analysis of milk, 10 mL of quarter milk was aseptically collected from 
the teats previously cleaned and disinfected and after the discard of first squirts. Samples 
were refrigerated until arrival at laboratory facilities. Ten μL of each sample was spread 
onto blood agar plates (5% bovine blood) and incubated at 37°C for the bacteriological 
analysis as previously described (Oliver et al., 2004). Plates were evaluated after 24 and 
48 h, and colonies were isolated and identified by biochemical tests following Hogan et al. 
(1999) and confirmed by API System (Rapid ID 32 Strep, Biomérieux City, Country). The 
somatic cell count of each sample was performed with Bentley Somacount 150 (Bentley 
Instruments City, Country). All isolates were stored at -80°C in Microbank Bacterial 
Preservation System (Thermo Fisher, City, Country). Immediately after thawing, the 
isolates were subcultured on blood agar plate (5% of blood, Oxoid) and thereafter grown 
in BHI broth for 24 h at 37°C. Antibiotic sensitivity of each strain was tested by Kirby-
Bauer disk diffusion method. The drugs most widely used in the treatment of bovine 
mastitis (penicillin, ampicillin, amoxicillin/clavulanic acid, oxacillin, 1st, 3rd and 4th 
generation cephalosporins, norfloxacin, nafcillin/penicillin/streptomicin, rifaximin, tylosin, 
kanamicin, tiamphenicol, sulfamethoxazole/trimethoprim) were tested. 
2.2. Minimum inhibitory concentration (MIC) assay 
Bacteriostatic activity of cell-free supernatants (CFS) containing bacteriocins (sample A) 
was tested using MIC assay against each pathogen strain, according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines. Serial two-fold dilutions of each 
supernatant were performed in 100µL of BHI broth supplemented with 5% Fetal Calf 
Serum (FCS), in 96-well microplates. For each pathogen, a 106 cfu/mL inoculum was 
prepared, then 10 µL of bacterial inoculum was added to each well and the plates were 
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incubated for 24h at 37°C. In addition, for each test a sterility control was performed in a 
separate well and checked for any growth after incubation. The antimicrobial activity of 
each supernatant was expressed as arbitrary units/mL (AU/mL). One AU was defined as 
the reciprocal of the highest serial twofold dilution that completely inhibited bacterial 
growth (Todorov et al., 2011). 
The sensitivity of three strains (S. agalactiae MB386, S.uberis MB707 and S.dysgalactiae 
MB280) to a nisin solution containing 150 µg/mL of pure nisin was also evaluated and 
compared to the results obtained with CFS, in order to estimate the amount of 
bacteriocin in the supernatants. 
2.3. Minimum bactericidal concentration (MBC) assay 
To test bactericidal effect of bacteriocins, minimum bactericidal concentration (MBC) was 
assayed for each bacteriocin against each pathogen strain. Ten µL of each dilution 
representing the MIC endpoint of two more concentrated dilutions were plated onto 
blood agar plates (5% bovine blood) and incubated overnight at 37°C. Each dilution was 
plated in duplicate and colonies of growth were counted. The MBC was defined as the 
lowest concentration showing ≥99% killing (CLSI, 1999) and the minimum dilution of 
bacteriocins that killed the pathogens was expressed in AU/mL (see above). 
 
3. IDENTIFICATION OF ANTIBACTERIAL MOLECULES 
3.1. Partial purification of antibacterial molecules 
Partial purification of antibacterial molecules produced by active strains of Lactococcus 
spp. was performed by the adsorption-desorption method as described by Yang et al. 
(1992) and Baljinder et al. (2013). Briefly, after growth, the culture broths were adjusted 
to pH 6.5, the cells were deactivated by heating at 70°C for 25 min, and left for for 3h at 
4°C to allow the adsorption of bacteriocins onto the bacterial cell walls. Subsequently, 
bacterial cells were harvested by centrifugation at 15,000g for 15 min at 4°C, washed with 
5 mM sodium phosphate buffer (pH 6.5) and resuspended in 100 mM NaCl at pH 2.0 to 
allow the bacteriocins to be desorbed. After 1h incubation at 4°C, cell suspensions were 
centrifuged at 29,000g for 20 min and then the obtained pre-purified extracts (sample B) 
were filter-sterilized by passing through a 0.2 m pore size cellulose acetate membrane. 
The extracts were subsequently fractionated by ultrafiltration through a 1 kDa molecular 
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weight cut-off (MWCO) ultrafiltration membrane (Millipore, Darmstadt, Germany) and 
tested for antibacterial activity against the indicator strain by spot-on-lawn test as 
indicated above (see chapter 1.2). 
3.2. Sodium Dodecyl Sulphate–Polyacrylamide Gel Electrophoresis (SDS–PAGE) 
and antibacterial activity test in gel 
Cell-free supernatant (sample A) and partially purified bacteriocin extract (sample B) 
ultrafiltration (1 kDa) permeates and retentates were mixed with SDS–PAGE native 
sample buffer. Separation was performed on a 15 % polyacrylamide (PAA) resolving gel in 
TRIS–glycine–SDS buffer on SE 250 mini-vertical gel electrophoresis system (Hoefer Inc., 
Holliston, MA, USA). PageRulerTM Plus Prestained Protein Ladder (mol wt 10–250 kDa; 
Thermo Fisher Scientific Baltics; Vilnius, Lithuania)  and Spectra Multicolor Low Range 
Protein Ladder (mol wt 1,7-40 kDa; Thermo Fisher Scientific Baltics; Vilnius, Lithuania) 
were used as a protein molecular weight markers. The electrophoresis was run at 23°C 
and 50 V for the first 0.5 h and then at 100 V for another 2 h. Gels were stained with 
Coomassie brilliant blue G-250. The molecular weights of obtained protein bands were 
estimated by calculating the relative migration distance (rf) values (Hames, 1998). For 
antibacterial activity test PAA gel was fixed with 50% methanol and 10% acetic acid in 
milliQ-treated water for 15 min at 25°C, washed in milliQ-treated water for 2 h at 25°C 
changing water every 15 minutes, then aseptically placed on S. agalactiae soft agar (BHI 
agar (1%) supplemented with 5% of FCS) and overlaid with the same soft agar, but  
inoculated with 106 cfu/mL of the indicator strain. The plates were incubated at 37°C for 
18–24 h and the inhibition zone of growth was observed. 
3.3. Ultra Performance Liquid Chromatography/Electrospray Ionization-High 
Resolution-Mass Spectrometry (UPLC/ESI-HR-MS) analysis  
Partially purified bacteriocin extract (sample B) ultrafiltration (1 kDa) retentates were 
fractionated by ultra-performance liquid chromatography (UPLC) carried out on an 
Acquity UPLC separation module (Waters, Milford, MA, USA) and analyzed with a photo 
diode array (PDA) eLambda detector (Waters) and a high resolution Q Exactive hybrid 
quadrupole-Orbitrap mass spectrometer (HR-MS, Thermo Scientific, San Jose, CA, USA) 
interfaced through an electrospray ionization (ESI) source. Samples were separated on an 
Aeris WIDEPORE XB-C4 column (2.1 × 150 mm, 3.6 μm) (Phenomenex, Torrance, CA, USA) 
kept at 40 °C. The eluents were: 0.1% trifluoroacetic acid (TFA) in milliQ-treated water 
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(solvent A) and 0.1% TFA in acetonitrile (solvent B). The UPLC separation was performed 
by using a linear elution gradient (10% to 55% of solvent B in 13.7 min) at a flow rate of 
0.2 mL/min. Proteins in the eluate were detected with a PDA detector at 210 nm and 
subsequently analyzed by MS using full scan analysis in the range 300–2000 m/z. The 
resolution was set at 140K. The AGC target was 5e5. The maximum ion injection time was 
100 ms. The MS data were automatically processed using Xcalibur software (Thermo 
Scientific), and protein mass deconvolution was performed using Xtract software (Thermo 
Scientific). 
3.4. Lactococcus lactis subsp. lactis SL208 genome sequencing  
Whole DNA of L. lactis subsp. lactis SL208 was extracted using the DNeasy blood and 
tissue kit (Qiagen, I) following the manufacturer instructions and was subjected to quality 
control. After library preparation with the Nextera XT sample preparation kit (Illumina), 
sequencing was performed using the Illumina MiSeq platform with a 2 × 250 paired-end 
run. Reads were analyzed and quality checked using FastQC (Andrews, 2010) and a 
specifically designed python script. Genome assembly was performed using Mira4 
(Chevreux et al., 1999), while genome annotation was performed using the PROKKA 
software (version 1.1). NCBI Protein Basic Local Alignment Search Tool (BLAST) was used 
to identify protein amino acids sequences, while the alignment of Lactococcin G, 
Enterocin C2 and SL208 Lactococcin-like protein was performed using the ClustalW 
software alignment tool (version 2.1). 
 
4. INTERACTION OF BACTERIOCINS OR LIVE LACTOCOCCAL CULTURES 
WITH MAMMARY EPITHELIAL CELLS 
4.1. Bovine mammary epithelial cell culture 
BME-UV1 cells were cultured at 37°C with 5% CO2 in the following medium: 50% 
Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 Ham (DM/F12, Gibco), 30% 
RPMI 1640 (Gibco), 20% NCTC 135 (Gibco), containing 0.1% lactose, 0.1% lactalbumin 
hydrolysate, 1.2 mM glutathione, 10 μg/ml L-ascorbic acid, 1 μg/ml hydrocortisone, 1 
μg/ml insulin, 5 μg/ml transferrin, and 0.5 μg/ml progesterone. The cells were grown to 
confluence in 6-wells plates for 58 h in complete medium supplemented with 10% Fetal 
Calf Serum (FCS). To evaluate the role of serum addiction, the cells were grown to 
confluence and maintained for 4, 8, 24, 34 and 58 h with 10%, 5% or without FCS; at each 
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time point both culture medium and cells were collected and tested for enzymes 
production. To test the effect of the treatments, the 58h old cells were washed twice with 
Hanks' Balanced Salts Solution (HBSS) and maintained in the complete medium without 
FCS until the addiction of CFSs or live lactococcal cultures (see below). Trypan blue 
solution (0.4%, Sigma-Aldrich) was used to assess cell viability: 20 μL of cells were 
suspended in 80 μL of diluted solution (Trypan blue/PBS, 1/5) and the rate of viable cells 
was calculated using a Burker cell counting chamber.  
4.2. Challenge with bacteriocins and live cultures of Lactococcus lactis subsp. 
lactis 
Each preparation containing LL11 or SL153 bacteriocin was obtained after 48h incubation 
of lattococci in RPMI medium. Antibacterial activity of such CFSs was assayed with the 
MIC test to measure the antibacterial activity. For the evaluation of enzymes and 
cytokines production by epithelial cells, CFSs were added to 6-wells cell culture plate to a 
final concentration of 10% in FCS-free medium. Moreover, to test the stimulation of 
epithelial cells by lactococcal live cultures , 30 μL of a suspension (104 cfu/mL) of each 
bacteriocin producing-lactococcus strain (LL11 or SL153 or SL208) were added to distinct 
wells and after 4h, 8h, 15h, 24h of stimulation both culture medium and cells were 
collected separately and stored at -20°C. Bacterial growth and antimicrobial activity of 
extracellular compound were also assayed at such time points. Aliquots of 150 μL 
containing 3 x 106 BME-UV1 cells were suspended in 750 μL of RNAlater (Sigma-Aldrich) 
and stored at -80 °C until RNA extraction. Production of antibacterial enzymes was tested 
on both epithelial cells and culture medium, while pro-inflammatory cytokine expression 
was assayed on the cells of each well. 
4.3. N-acetil-β-D-glucosaminidase and Lysozyme assays 
The amount of N-acetil-β-D-glucosaminidase (NAGase) and Lysozyme (LZ) were assayed in 
both supernatants and cells using a fluorescence-based procedure. In order to disrupt the 
cell membrane and allow the complete release of enzymes, the cells were shaken with 
150-212 μm glass beads (Sigma-Aldrich) and then harvested by centrifugation. Trypan 
blue solution (0.4%, Sigma-Aldrich) was used to assess cell viability according to the 
manufacturer's instructions. 
NAGase activity was assessed in duplicate by a fluorometric assays according to Kitchen et 
al. (1984), on a microplate fluorometer (Fluoroskan Ascent, Thermo Labsystem, FL). Each 
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sample was incubated with 4-methylumbelliferyl-N-acetyl--D-glucosamidine (MUAG, 
Sigma-Aldrich) as a substrate. NAGase activity was measured as fluorescence increment 
on a microplate florimeter (Fluoroskan Ascent, Thermo Labsystem, FL) using 355 nm 
excitation and 460 nm emission. The concentration was calculated against a standard 
curve with a range of 0-200 μM of 4-methylubelliferone (4-MU, Sigma-Aldrich). Activity 
was expressed as pmol 4-methylubelliferone released/min at 25 °C catalysed by 1 µl of 
solution. 
LZ was assessed in duplicate by (EnzChek Lysozyme Kit, Invitrogen, CarlsbadCA, USA), 
which is based on the lysis of Micrococcus lysodeycticus labelled with fluorescine. LZ 
activity was assayed by measuring fluorescence increment after 30 min of incubation at 
37°C on a microplate fluorimeter at 494nm excitation and 518 nm emission 
(FluoroskanAscent, Thermo Labsystem, FL, USA), against a standard curve with a range of 
8-500 units. One unit of LZ is defined as the quantity of enzyme that produces a decrease 
in turbidity of 0.0001 OD units per min at 450 nm measured at pH 7.0 (25 °C) using 0.3 
mg/mL. 
4.4. Real-time RT-PCR for mRNA quantification 
After thawing, cells were centrifuged at 5000 x g for 18 min, to remove RNAlater and then 
washed once with PBS. Total RNA was extracted using Illustra Mini RNA isolation kit (GE 
healthcare Europe) according to manufacturer’s instructions, and stored at -20°C. RNA 
quantification and purity was estimated using spectrophotometer ND-100 (Nanodrop 
Technologies inc. USA). For RNA retrotranscription, QuantiTect Reverse Transcription Kit 
(Qiagen, I) was used and 0,1 µg of RNA was reverse transcribed following the 
recommended procedure in a final volume of 20 μL. A negative control without enzyme 
was added to exclude DNA contaminations in RNA. Quantitative real-time PCR (qPCR) was 
performed using EvaGreen fluorescent detection system and the Eco Real-Time PCR 
System (Illumina Inc., USA). In each reaction, 3 μL of cDNA equivalent to 3 ng of total RNA 
were amplified in a 15 μL mixture containing 100nM reverse and forward primer each 
(GAPDH and TNFα) or 200nM each (IL-8). In each plate, GAPDH was run as housekeeping 
gene and a negative and positive control were included. Each sample was processed in 
triplicate. 
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The primers for GAPDH, TNFα and IL-8 are listed in the table 2. 
 
Table 2. Primer sequences with respective melting temperature (Tm) and product size. 
Target cDNA Primer (5’-3’) Tm 
(°C) 
Product size  Source 
TNFα F:CTGGTTCAGACACTCAGGTCCT 
R:GAGGTAAAGCCCGTCAGCA 
62.1  
58.8 
183 bp Tomasinsig et al. (2010) 
IL-8 F:CCTCTTGTTCAATATGACTTCCA 
R:GGCCCACTCTCAATAACTCTC 
56.26 
57.81 
189 bp Günter et al. (2010). 
GAPDH F:CCTGGAGAAACCTGCCAAGT 
R:GCCAAATTCATTGTCGTACCA 
59.4 
55.9 
214 bp Tomasinsig et al. (2010) 
 
 
The thermal-cycling program was different for TNFα or IL-8 in the annealing/extension 
step: initial denaturation/activation (95°C for 3min), 45 cycles of denaturation (95°C for 
10 s), annealing/extension (62°C for 15 s for TNFα, or 59°C for 15 s for IL-8) and melting 
curve analysis. 
At the cycle number at witch fluorescence signal intersected with the threshold, the Cq 
value of a sample was set and used for quantification. The specificity of the reaction was 
checked post-amplification by melt curve analysis using high resolution melting analysis 
(HRMA). In the Eco Real-Time PCR System (Illumina Inc., USA) fluorescence data were 
registered every 0,1°C, from 55°C to complete denaturation of DNA at 95°C.  
 
4.4.1 Data Analysys of Real-Time RT-PCR 
For relative quantification of mRNA, the Cq values of the target gene transcripts were 
normalized against the reference gene GAPDH, and the results were expressed as 
normalized fold expression relative to the control (not stimulated cells). 
Because the amplification efficiencies of the target and the reference genes were not 
equal the normalization of the samples to a single reference gene was made with the 
Pfaffl method (Pfaffl, 2001) that does not assume equal or 100% amplification efficiency 
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and incorporates the experimentally determined efficiencies of the target and reference 
genes to correct for any differences.  
The calculations for this method are shown below: 
 
 
 
 
 
5. STATISTICAL ANALYSIS 
The analysis of data has been performed with the software SPSS Statistics version 21.0 
(IBM, USA). Means were compared by Two-way ANOVA (Analysis of Variance) and Scheffè 
post-hoc test. Time and treatment variables were used as main effects and the NAGase, 
Lysozyme and cytokine expression as the dependent variables. One-way ANOVA was 
applied when the time variable was not significant and also to highlight differences 
among intracellular and extracellular localization of enzymes. Results were considered as 
statistically significant at P values <0.05. 
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RESULTS AND DISCUSSION 
 
1. SCREENING OF LAB STRAINS FOR ANTIBACTERIAL ACTIVITY 
 
Sixty-five strains from the collection of Centro Sperimentale del Latte were tested for 
their antibacterial activity against Streptococcus agalactiae MB386 by spot-on-lawn assay. 
This pathogen was used as indicator strain, because S. agalactiae is known to exhibit high 
sensitivity to bacteriocins (Wu et al., 2007) and the 3 strains tested (MB386, MB90, 
MB98) showed high and comparable sensitivity. As bacteriocin production by LAB is a 
growth-associated process (Cintas et al., 2011) starting at early stationary phase, and 
reaching its peak toward the end of this phase (De Vuyst and Vandamme, 1991), the 
selection of the best medium to grow the bacteria allowed the optimisation of CFS 
antibacterial activity (Table 1.1). The acid-extraction method was found to maximize the 
amount of bacteriocins released in the CFSs allowing the release of peptide from 
producer cell surfaces as suggested by Yang et al. (1992) and thus the potency of CFSs. 
MRS medium allowed the highest bacterial proliferation and exerted high antibacterial 
activity, which was enhanced after the acidification method. Furthermore a commercial 
medium assured a more constant and better characterized composition. Cell-free culture 
supernatants (CFS) obtained by bacteriocin producers cultivated in acidified MRS medium 
were used to screen the LAB strains for antibacterial activity. Among the 65 strains, only 
3, belonging to the species Lactococcus lactis subsp. lactis (LL11, SL153 and SL208), 
showed antibacterial activity against S. agalactiae MB386. Lactococcus lactis subsp. lactis 
LL11 strain had been isolated from bovine milk, while SL153 and SL208 came from natural 
starter for dairy processing. This result is in disagreement with a previous paper (Riley and 
Wertz, 2002) which proposed that 99% of all bacteria may produce at least one 
bacteriocin. Even though different culture conditions, pH, temperature and stress factors 
could interfere with bacteriocin production (Drider et al., 2006). Biosynthesis of 
bacteriocins occurs in bacterial cells when anti-competitors activity is necessary (e.g. 
against invasion of other strains or species into a niche) and these proteins have also a 
role in quorum sensing process, mediating microbial interaction (Drider et al., 2006). 
These characteristics, together with the three-component regulation of genes activation 
that needs a threshold level requirement for the auto-induction activation (Balciunas et 
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al., 2013), make hard the comprehension of basic mechanisms of bacteriocin production 
or failure. 
 
Table 1.1 MIC values of cell-free culture supernatants extracted from different media and 
from acidified MRS medium against reference strain Streptococcus agalactiae MB386. 
 
Medium 
(broth) 
Lactococcus lactis subsp. lactis LL11 
UFC/mL 
 Diameter of inhibition zone 
(mm) Spot-on-lawn assay 
MIC (AU/mL) 
TGE1  1x109 UFC/mL 10.0 128 
TGE2  / 0.0 1.5 
GYB2  1x108 UFC/mL 2.0 6 
GYB1 2x107 UFC/mL 0.0 1.5 
SG  1x109 UFC/mL 11.5 128 
MRS 2x109 UFC/mL 14.0 128 
Acidified MRS 2x109 UFC/mL 15.0 256 
 
2. ANTIBACTERIAL ACTIVITY AGAINST MASTITIS PATHOGENS  
 
Antibiotic sensitivity patterns of mastitis isolates, determined by plate diffusion method, 
showed that all strains were resistant to at least one of antibiotics tested. E. faecalis 
evidenced a particular resistant pattern: three strains were resistant to oxacillin and 
demonstrated intermediate susceptibility to fluoroquinolones. In addiction 2 out of 4 
were also resistant to penicillin, macrolides and tiamphenicol and one of them also 
showed no sensitivity to first generation cephalosporin.  
All S. agalactiae strains were resistant to oxacillin and 2 out of 3 strains were also 
resistant to rifaximin and macrolides. In addition, macrolides  were not effective on one S. 
uberis and both S. dysgalactiae strains.  
A clear resistance to penicillin and ampicillin was evidenced by S. aureus with overall 8 
resistant strains, 2 of them also resistant to amoxicillin/clavulanic acid. Two strains were 
MRSA and showed also resistance to fourth generation cephalosporin (Table 2.1). 
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Antimicrobial activity of the 3 active CFSs was evaluated against the pathogens. Among 
streptococcal strains, the most sensitive species to antibacterial activity of CFS were S. 
agalactiae, E. faecalis and S. uberis which showed the highest MIC values reaching 384 
and 256 AU/mL. While the 3 S. agalactie strains (MB90, MB98, MB386) demonstrated an 
identical sensitivity to all CFS, the different strains of E. faecalis and S. uberis showed an 
evident difference in their antimicrobial susceptibility to the same bacteriocin. In 
particular E. faecalis strains displayed up to 7-fold higher sensitivity in the MIC assay 
when tested against  SL153 CFS with the values ranging  2-256 AU/mL. E. faecalis strain 
MB330 demonstrated a marked resistance to all bacteriocins tested showing a MIC of 2 
AU/mL when tested with LL11 CFS and SL153 CFS, and no sensitivity against SL208 CFS. S. 
uberis reached 5 dilution differences among strains when tested against SL153 CFS. The 
two S. dysgalactiae strains were the most resistant to LL11 and SL153 CFSs, and showed 
MIC values of 32 and 4 AU/mL when  tested against SL208 CFS. 
Among staphylococcal strains high sensitivity was showed by S. aureus MB390 that 
reached a MIC value of 256 AU/mL in the presence of SL153 CFS. The lower inhibition 
levels was observed for S. aureus ATCC29213, MB221, MB254 and MB786 strains and for 
the two MRSA strains tested. Overall, no resistant strains were evidenced with the MIC 
test aainst LL11 and SL153 CFSs. To the contrary 53% of S. aureus and one of the 3 
coagulase negative staphylococci (CNS) strains were resistant to SL208 CFS. As well as S. 
uberis and E. faecalis, S. aureus and CNS demonstrated a large variability in the sensitivity 
to lactococcal bacteriocins (see tables 2.2 and 2.3). 
Lactococcus lactis subsp. lactis SL153 showed the highest inhibitory activity against the 
pathogens in the MIC test, while SL208 CFS displayed the lowest antibacterial activity 
since 10 pathogens were resistant. Only S. aureus MB290 and both S. dysgalactiae strains 
(MB280 and MB324) were equally or even more sensitive to SL208 CFS compared to 
SL153 CFS. To the contrary, SL153 and LL11 CFSs were always active. The MBC values 
overlapped the respective MIC values or differed by a maximum of a dilution for all 
strains (Tables 2.2 and 2.3). 
Although antibiotics still represent the election treatment for mastitis, the biggest 
challenge in the modern dairy industry is the reduction of the antibiotics use in food 
production animals (Bradley, 2002). Furthermore, the dairy industry could benefit from 
the development of safe antimicrobial agents and bacteriocins could be an attractive 
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alternatives to antibiotics (Pieterse and Todorov, 2010) avoiding withdrawal period and 
residues in milk. 
A considerable variability of bacteriocin sensitivity was observed among both bacterial 
species and different strains belonging to the same species. It should be noticed that the 
antibacterial activity was observed also against tose species which are well known to 
develop antimicrobial resistance, such as E. faecalis and S. aureus (Piper et al., 2009). 
Nevertheless, E. faecalis together with S. agalactiae showed the highest MIC values, 
indicating a noticeable sensitivity to bacteriocins. It should be pointed out that, despite 
the differences in sensitivity, bacteriocins were able to inhibit and to kill the pathogens at 
the same concentration, confirming bactericidal activity of bacteriocins. 
Sensitivity of 3 different Streptococcus spp. strains to nisin was also tested. The pathogen 
strains were selected among those showing no resistance to any bacteriocin preparation 
and belonged to 3 different species, S. agalactiae MB386, S. uberis MB707, S. 
dysgalactiae MB280. They were used to evaluate the antibacterial activity of pure nisin 
(150 µg/mL). The potency of this preparation was 16-64 times higher than that of 
bacteriocin extracts against S. agalactiae; 8-32 times against S. uberis and the same for 
SL208. For LL11 and SL153, it was 64 times higher against S. dysgalactiae (Table 2.4). The 
comparison of the inhibitory activity of nisin solution with the three active CFSs suggested 
that a small amount of bacteriocin was contained in our preparations. Nevertheless, their 
antibacterial activity confirmed the well-known efficacy of bacteriocins even at very low 
amounts, which characteristic could be advantageous in therapeutic use. 
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Table 2.1 Antibiotic susceptibility pattern of strains tested: the number of resistant (R) or 
sensitive (S) strains are indicated in the corresponding columns. 
Antibiotic  
S. 
agalactiae 
(n=3) 
S. 
dysgalactiae 
(n=2) 
E. 
faecalis 
(n=4) 
S. uberis 
 (n=3) 
S. 
aureus 
(n=13) 
CNS 
(n=3) 
R S R S R S R S R S R S 
Penicillin    3   2 2 2   3 8 5 1 2 
Ampicillin   3   2 1 3   3 8 5 1 2 
Amoxicillin/clavulanic acid   3   2   4   3 2 11   3 
Oxacillin 3     2 3 1   3 2 11   3 
1st generation cephalosporin   3   2 1 3   3   13   3 
3rd generation cephalosporin   3   2   4   3   13   3 
4th generation cephalosporin   3   2   4   3 2 11   3 
Norfloxacin    3   2   4   3 1 12   3 
Rifaximin 2 1   2 2 2   3   13   3 
Nafcillin/Penicillin/Streptomycin    3   2   4   3   13   3 
Tylosin 2 1 2   2 2 1 2 1 12 1 2 
Spiramycin 2 1 2   2 2 1 2   13 1 2 
Tiamphenicol   3   2 2 2   3 1 12   3 
Sulfamethoxazole/trimethoprim   3   2 4   3   2 11   3 
 
 
Table 2.2 MIC and MBC values of LL11, SL153, SL208 CFSs against streptococcal strains 
expressed as AU/mL. 
2.2 LL11 
Microorganism MIC values  MBC values 
S. agal. (MB386, MB90, MB98) 256.0 256.0 
E. faec. MB330 2.0 2.0 
E. faec. MB561 64.0 32.0 
E. faec. MB562 128.0 64.0 
E. faec. MB706 64.0 32.0 
S. uberis MB705 64.0 64.0 
S. uberis MB707 16.0 8.0 
S. uberis MB300 8.0 4.0 
S. dysgal. MB280 1.5 not killed 
S. dysgal. MB324 1.0 not killed 
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2.2 SL153 
Microorganism MIC values MBC values 
S. agal. (MB386, MB90, MB98) 384.0 384.0 
E. faec. MB330 2.0 2.0 
E. faec. MB561 128.0 128.0 
E. faec. MB562 128.0 128.0 
E. faec. MB706 256.0 256.0 
S. uberis MB705 256.0 128.0 
S. uberis MB707 32.0 32.0 
S. uberis MB300 8.0 8.0 
S. dysgal. MB280 1.0 1.0 
S. dysgal. MB324 2.0 2.0 
   
 
2.2 SL208 
Microorganism MIC values  MBC values 
S. agal. (MB386, MB90, MB98) 64.0 64.0 
E. faec. MB330 res not killed 
E. faec. MB561 8.0 4.0 
E. faec. MB562 16.0 16.0 
E. faec. MB706 8.0 4.0 
S. uberis MB705 64.0 64.0 
S. uberis MB707 4.0 2.0 
S. uberis MB300 4.0 4.0 
S. dysgal. MB280 32.0 16.0 
S. dysgal. MB324 4.0 4.0 
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Table 2.3 MIC and MBC values of LL11, SL153, SL208 CFSs against staphylococcal strains 
expressed as AU/mL. 
2.3 LL11 
Microorganism MIC values  MBC values 
S. aureus (ATCC 29213) 2.0 not killed 
S. aureus MB221 1.0 1.0 
S. aureus MB254 2.0 1.0 
S. aureus MB351 16.0 8.0 
S. aureus MB390 64.0 24.0 
S. aureus MB439 24.0 16.0 
S. aureus MB501 16.0 12.0 
S. aureus MB512 24.0 16.0 
S. aureus MB535 6.0 6.0 
S. aureus MB543 32.0 16.0 
S. aureus MB781 64.0 32.0 
S. aureus MB786 4.0 2.0 
S. aureus MB798 32.0 16.0 
MRSA MB508 1.0 not killed 
MRSA MB628 2.0 1.0 
CNS MB307 8.0 8.0 
CNS MB309 48.0 24.0 
CNS MB316 12.0 12.0 
 
2.3 SL153 
Microorganism MIC values MBC values 
S. aureus (ATCC 29213) 8.0 8.0 
S. aureus MB221 8.0 4.0 
S. aureus MB254 12.0 8.0 
S. aureus MB351 24.0 24.0 
S. aureus MB390 256.0 256.0 
S. aureus MB439 64.0 64.0 
S. aureus MB501 96.0 96.0 
S. aureus MB512 64.0 64.0 
S. aureus MB535 12.0 12.0 
S. aureus MB543 64.0 64.0 
S. aureus MB781 64.0 32.0 
S. aureus MB786 12.0 12.0 
S. aureus MB798 48.0 48.0 
MRSA MB508 2.0 1.0 
MRSA MB628 4.0 4.0 
CNS MB307 16.0 16.0 
CNS MB309 64.0 64.0 
CNS MB316 48.0 48.0 
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2.3 SL208 
Microorganism MIC values  MBC values 
S. aureus (ATCC 29213) res not killed 
S. aureus MB221 res not killed 
S. aureus MB254 res not killed 
S. aureus MB351 2.0 1.0 
S. aureus MB390 256.0 128.0 
S. aureus MB439 2.0 1.0 
S. aureus MB501 2.0 1.0 
S. aureus MB512 2.0 2.0 
S. aureus MB535 res not killed 
S. aureus MB543 6.0 6.0 
S. aureus MB781 1.0 1.0 
S. aureus MB786 res not killed 
S. aureus MB798 res not killed 
MRSA MB508 res not killed 
MRSA MB628 res not killed 
CNS MB307 res not killed 
CNS MB309 2.0 not killed 
CNS MB316 2.0 not killed 
 
 
 
Table 2.4 MIC expressed as arbitrary units (AU/mL) of cell-free supernatants and pure 
nisin solution (150 µg/mL) against three sensitive Streptococcus spp. strains. 
 
Strain 
LL11 SL153 SL208 Nisin 
S. agalactiae MB386 256.0 384.0 64.0 4096.0 
S. uberis MB707 16.0 32.0 4.0 256.0 
S. dysgalactiae MB280 1.5 1.0 32.0 32.0 
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3. IDENTIFICATION OF ANTIBACTERIAL MOLECULES 
 
Identification of antibacterial molecules produced by L. lactis subsp. lactis strains LL11, 
SL153 and SL208 was performed in partially purified bacteriocin extracts obtained by the 
adsorption-desorption method (sample B). First, the activity of these extracts was verified 
by the spot-on-lawn test. It gave positive results indicating that the antimicrobial 
compound was successfully extracted and purified applying this method. Subsequently, 
the purified bacteriocin extracts were fractionated by ultrafiltration through 1 kDa 
molecular weight cut-off (MWCO) ultrafiltration membrane. The partially purified extract 
1 kDa ultrafiltration permeates of Lactococcus lactis subsp. lactis strains LL11, SL153 and 
SL208 did not show any antibacterial activity against the indicator strain (S. agalactiae 
MB386) as elucidated by spot-on-lawn test (Figure 3.1 A,B,C). To the contrary, the 
retentates A and B of all three strains maintained their antimicrobial activity indicating 
that the molecules, conferring antibacterial activity to these strains, are larger than 1 kDa 
(Figure 3.1). Ultra-filtered (1 kDa) retentates were further subjected to the SDS–PAGE 
analysis. 
Separation of retentates A by SDS–PAGE highlighted two protein bands for each of the 
three samples: the smaller one of approximate molecular mass of 4 kDa and the large 
over-loaded spot with the approximately double lower mass limit (Figure 3.2). Retentates 
B did not evidentiate any band on SDS–PAGE probably due to the low concentrations of 
purified molecules, not detectable by Coomassie staining. Nevertheless both, sample A 
retentates and, to a lesser extent, sample B retentates showed the corresponding zones 
of inhibition after separation by the SDS–PAGE (under non-reducing conditions) when 
overlaid with S. agalactiae indicator strain in soft agar (Figure 3.2) confirming the 
presence of antibacterial molecules larger than 1 kDa. 
Partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentates were 
subsequently fractionated by ultra-performance liquid chromatography (UPLC) and 
analyzed with photo diode array (PDA) detector and a high resolution mass spectrometer 
(HR-MS). Analysis of LL11 and SL153 sample B 1 kDa ultrafiltration retentates highlighted 
the presence of a major peak at 11.8th min in PDA (at 210 nm) chromatogram (Figure 3.3). 
The exact masses of the molecules corresponding to those peaks of LL11 and SL153 
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extracts were found to be 3353.55 Da (Figure 3.4). It is interesting to note that other two 
forms, differing in 16 Da and 32 Da from the main form, were present (Fig. 3.4 B and 
Supplementary material Figure S2), which could be attributed to the protein with one or 
two oxidized methionines, respectively. According the exact mass, these molecules were 
attributed to the Nisin A (Piper et al., 2011) and its two forms with oxidized Met17 and 
Met21. L. lactis subsp. lactis strain SL208 Sample B 1 kDa ultrafiltration retentate 
highlighted the presence of two major peaks: at 11.8th min (peak 1) and at 6.1th min (peak 
2) (Figure 3.3). The exact mass of the molecule corresponding to the strain SL208 partially 
purified extract 1 kDa ultrafiltration retentate chromatographic peak 1 was found to be 
2900.25 Da (Supplementary material Figure S3), while the SL208-peak 2 indicated a 
molecule with the exact mass of 3867.13 (Supplementary material Figure S4). The exact 
masses of the molecules corresponding to the peak 1 and peak 2 were as those reported 
for Lacticin 481 (Piard et al., 1993) and Enterocin C2 (Maldonado-Barragán et al., 2009), 
respectively. 
 
 
3.1 A     B   C  
Figure 3.1 Spot-on-lawn test of bacteriocin extracts of Lactococcus lactis subsp. lactis 
strains: LL11 (A), SL153 (B) and SL208 (C) against S. agalactiae MB386. APERM, sample A 
(CFS) 1 kDa ultrafiltration permeate; ARET, sample A 1 kDa ultrafiltration retentate; BPERM, 
sample B (pre-purified bacteriocin extract) 1 kDa ultrafiltration permeate; BRET, sample B 1 
kDa ultrafiltration retentate. 
  
ARET 
BRET 
APERM 
BPERM 
APERM APERM ARET ARET 
BRET BRET BPERM BPERM 
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A)   
 
 B)  
 
 C)  
Figure 3.2 SDS–PAGE separation of fractionated (UF 1 kDa) bacteriocin extracts (left) and 
their inhibitory activity against S. agalactiae MB386 (right). Lactococcus lactis subsp. lactis 
strains: A) LL11; B) SL153; C) SL208. Lanes: 1, protein molecular weight ladder; 2, 
retentate A; 3, retentate B; 4, permeate A; 5, permeate B. 
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Figure 3.3 PDA (210 nm) chromatograms of L. lactis subsp. lactis strain LL11, SL153 and 
SL208 partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentates 
fractionated by UPLC. 
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Figure 3.4 HR-MS spectrum (A) and deconvoluted MS spectrum (B) of L. lactis subsp. lactis 
LL11 partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentate peak 
eluting at 11.8 min. 
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In two recent studies, the efficacy of nisin in the treatment of clinical and subclinical 
mastitis was compared with that obtained with antibiotic administration. Clinical mastitis 
caused by S. aureus or S. agalactiae (Cao et al., 2007) and subclinical mastitis by S. aureus, 
coagulase-negative staphylococci, S. agalactiae, S. dysgalactiae or S. uberis were 
considered (Wu et al, 2007). Both studies concluded that administration of nisin was 
effective in the treatment of mastitis caused by several mastitis pathogens in lactating 
dairy cows. Nisin was also tested for its efficacy in a post-dipping formulation: Ambicin® N 
showed a reduction of S. aureus (62%), S. agalactiae (99%) and S. uberis (67%) in 
experimentally challenged teat surfaces (Sears et al., 1992). In our study, a considerable 
variability of bacteriocin sensitivity was observed both among the species and in the 
different strains belonging to the same species. According to results obtained by Cao et 
al. (2007) none of the strains tested were resistant to nisin-containing CFS. Nevertheless, 
of 13 S. aureus strains, 60% were resistant to β-lactams, 15% showed resistance to fourth 
generation cephalosporin and 15% were MRSA and were also resistant to amoxicillin 
enhanced by clavulanic acid. Our results are also in agreement with Wu et al. (2007), who 
observed the same high variability in the MIC of S. aureus after nisin treatment. 
Furthermore, we confirmed the sensitivity of MRSA strains to nisin (Piper et al., 2009) in 
bovine isolates. Despite variability of sensitivity intra species, the high MIC values reached 
against S. agalactiae, E. faecalis and S. uberis confirmed the marked sensitivity of 
streptococci to nisin (Klostermann et al., 2009). Considering the antibacterial activity of 
the two nisin producer strains LL11 and SL153, a general higher activity could be observed 
for the SL153 CFS, indicating higher amount of nisin produced. The comparison of 
sensitivity observed for both streptococcal and staphylococcal strains suggested a dose-
dependent sensitivity for the pathogens. Nevertheless, Streptococcus dysgalactiae MB280 
and MB324 strains had surprisingly the capability to resist to nisin activity. To the 
contrary, due to the higher sensitivity to SL208 CFS, we hypothesized  the presence of 
Enterocin C2, which is a class II bacteriocin with a different mode of action. Thus, it could 
be explained why a completely different pattern of susceptibility was shown for all the 
pathogens when exposed to SL208 CFS. Sparo et al. (2006) observed a sensitivity of 
mastitis isolates to enterocin MR99 and concluded that this bacteriocin could offer a 
therapeutic alternative to antibiotics in mastitis treatment. 
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3.1. L. lactis subsp. lactis SL208 genome sequencing, identification and analysis of 
bacteriocin-related genes 
As demonstrated above, L. lactis subsp. lactis SL208 antibacterial extract analysis showed 
the presence of two potentially antibacterial proteins with exact masses corresponding to 
those of already known bacteriocins: Lacticin 481 and Enterocin C2. In order to verify the 
presence or the absence of Lacticin 481 and Enterocin C2-encoding genes in L. lactis 
subsp. lactis SL208, a complete genome sequencing was performed: 1,533,479 paired 
sequences were generated with a mean length of 184 bases per read. Genome was 
assembled resulting in 113 large contigs (>1000 nt), a statistic value associated with 
contig lengths (N50) of 133,223 and an average coverage of 64.53×, for a total of 
2,657,411 bp, with a G+C content of 64.17%. After genome annotation, 2,657 protein-
coding genes were obtained. 
The presence of bacteriocin-encoding genes was further investigated (Table 3.1.1). DNA 
sequence analysis revealed the presence of Lacticin 481 (Lactococcin-DR)-encoding gene 
(PROKKA_01892; Table 3.1.1). The calculated exact mass of the protein encoded by this 
gene, corresponded to the protein peak (Peak 1) exact mass identified by UPLC/HR-MS 
analysis (2900 Da) and was attributable to the previously observed average mass of 
Lacticin 481 (Piard et al., 1993; Uguen et al., 2005). 
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Table 3.1.1 Bacteriocin-encoding genes (and corresponding proteins with calculated 
monoisotopic masses) found after genome sequencing of L. lactis subsp. lactis SL208. 
Signal peptides (SP) are indicated in red and putative SP in grey. 
No. Contig Proteins and their amino acid sequences Calculated 
monoisoto-
pic mass 
1 C4 >PROKKA_01529 Lactococcin-like family Pfam:PF04369.7 protein 
= hypothetical protein [Lactococcus lactis], WP_021214955, 
/note="Lactococcin-like family; pfam04369" 
MKNQLNFEVV SDEELLTTSG GQNSQQGEGG GYGSSNDTWG G 
4277 Da 
2 C4 >PROKKA_01535 Lactococcin-like family Pfam:PF04369.7 protein 
= hypothetical protein [Lactococcus lactis], WP_021214958, 
/note="Lactococcin-like family; pfam04369" 
MKNQLNFEVV SDEELMTING GQNMSMTDGG FEWVYAGGKP WFRIV 
5124 Da  
3 C4 >PROKKA_01540 Lactococcin-like family Pfam:PF04369.7 protein 
= hypothetical protein [Lactococcus lactis], WP_023163574, 
/note="Lactococcin-like family; pfam04369" 
MENQLNFEVI IDEELEKISG GYLPIPDMPG WRGQSTPWWW SLKQSNFSDA 
YSSFYNATH 
3937 Da 
(without 
predicted SP) 
4 C4 >PROKKA_01547 Lactococcin-like family Pfam:PF04369.7 protein 
= hypothetical protein [Lactococcus lactis], WP_003132257, 
/note="Lactococcin-like family; pfam04369" 
MENRLNFEAI SDDELAKIVG GGYPNNQSMN DVLHWLNGHN DGNPKQLPKW 
MGGLG 
3788 Da 
(without 
predicted 
SP) 
5 C8 >PROKKA_02390 bacteriocin, lactococcin 972 family 
= bacteriocin [Lactococcus lactis], WP_025016835, /note="Bacteriocin 
(Lactococcin_972)" 
MQTKKLLVST LILATLGGTL LQVSPVFAIN RSTYSQGSTN DKKYGMGAYA 
AYWNSYGNHW AEVTYGDKYG GRVVSVHANQ QAYAWLNTRW 
AEPATFYHSN GWVGTRSW 
 
Similar to: bacteriocin lactococcin 972 family Lactococcin 972, lcn972, 
O86283: 
MKTKSLVLAL SAVTLFSAGG IVAQAEGTWQ HGYGVSSAYS NYHHGSKTHS 
ATVVNNNTGR QGKDTQRAGV WAKATVGRNL TEKASFYYNF W 
9474 Da 
(without 
predicted 
SP) 
 
 
 
7377 Da 
(without  SP) 
6 C43 >PROKKA_01892 Lactococcin-DR (= Lacticin 481, lctA, P36499) 
MKEQNSFNLL QEVTESELDL ILGAKGGSGV IHAbuIAHEANM 
NAWQFVFDhbAA S 
2900 Da 
(without SP; 
post-
translationally 
modified) 
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Five other bacteriocin-encoding genes were found in the genome of the L. lactis subsp. 
lactis strain SL208. Surprisingly, none of these genes showed annotation similarity to 
Enterocin C2 encoding gene (entC2). Enterocin C2 (Acc. No. ACJ54160: region_name= 
"LcnG-beta", note= "Lactococcin G-beta; pfam11632"; part of Enterococcus faecalis strain 
C9901 plasmid pENTC, EU862242) is a non-modified plasmid-encoded protein synthetized 
as pre-bacteriocin with a consensus double-glycine leader sequence (Table 3.1.2). Pre-
protein (consisting of a signal peptide of 24 amino acids and a mature protein of 35 amino 
acids) monoisotopic mass was calculated to be 6447 Da, while mature bacteriocin 
Enterocin C2 (the length of 35 amino acids) calculated monoisotopic mass was 3867 Da. 
Experimentally measured exact mass of Enterocin C2 was found to be 3867 Da 
(Maldonado-Barrágan et al., 2009) which corresponded to the exact mass measured for a 
L. lactis subsp. lactis SL208 sample B UF 1 kDa retentate peak 2 protein. 
 
Table 3.1.2 Amino acid sequence of Lactococcin G- β subunit, Enterocin C2 and L. lactis 
subsp. lactis SL208 PROKKA_01540 pre-peptides deduced from their coding DNA 
sequences (signal peptides are indicated in red and putative predicted signal peptide in 
grey). Molecular weights of mature proteins (MW mp) are indicated. 
 
Protein Amino acid sequence MW mp Accession 
number 
Lactococcin G 
β subunit 
MKNNNNFFKGMEIIEDQELVSITGGKKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI 4110 Da ACR43770 
Enterocin C2 MKNIKNASNIKVIEDNELKAITGGGPGKWLPWLQPAYDFVAGLAKGIGKEGNKNKWKNV 3867 Da WP_ 
032492334 
Lactococcin-like 
protein 
(PROKKA_01540) 
MENQLNFEVI IDEELEKISGGYLPIPDMPGWRGQSTPWWWSLKQSNFSDAYSSFYNATH 3937 Da WP_ 
023163574 
 
 
In addition, none of the other five bacteriocin-related genes, identified after genome 
sequencing of L. lactis subsp. lactis SL208, had a similar calculated mass corresponding to 
that measured for the protein of peak 2 by UPLC/HR-MS (3867 Da). Due to entC2 
plasmidic localization, the possibility that incomplete sequencing of plasmid and thus the 
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lack of matching with the reference gene should be considered. However, the 
examination of the bacteriocin-encoding genes highlighted the presence of a gene 
(PROKKA_01540; Table 3.1.1) belonging to lactococcin-like family, which putatively 
encodes a protein with a calculated mass of 3937 Da. Detailed analysis of this sequence 
showed that PROKKA_01540 gene potentially encodes a peptide of 59 amino acids, 
containing the double-glycine leader sequence that probably, after processing, could give 
a mature peptide of 33 amino acids. Summing up, after the potential cleavage of the 
leader peptide (calculated with provisional models) the mature protein would be of 3937 
Da, thus 70 Da larger than that corresponding to SL208 peak 2. Post-translational 
modifications or amino acid replacements could explain the difference of molecular 
weight found through UPLC/HR-MS analysis and only then the 3867 Da protein identified 
in the antibacterial extract of L. lactis subsp. lactis SL208 peak 2 could be potentially 
attributed to the PROKKA_01540 mature transcript but not to any other SL208-encoded 
protein (taking into account that the genome sequencing coverage was sufficient to reject 
the hypothesis of an incomplete coverage). Furthermore, the bacteriocin Enterocin C2 is 
highly homologous to the other lactococcin-like family proteins (Balla et al., 1999) and, as 
demonstrated in this study, also to the protein encoded by PROKKA_01540 (Figure 3.1.1). 
 
 
Figure 3.1.1 Amino acids sequence alignment of Lactococcin G, Enterocin C2 and SL208 
Lactococcin-like protein (ClustalW 2.1 multiple sequence alignment). *, identical amino 
acids. 
 
Lactococcin G ACR43770         MKNNNNFFKGMEIIEDQELVSITGGKKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI 60 
Enterocin C2 WP_032492334      MKNIKNASN-IKVIEDNELKAITGGGPGKWLPWLQPAYDFVAGLAKGIGKEGNKNKWKNV 59 
                               *** :*  : :::***:** :****    **.*::***:*: *:.**  *****:****: 
 
Lactococcin G ACR43770          MKNNNNFFKGMEIIEDQELVSITGG--KKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI- 60 
SL208 Lactococcin-like protein  MENQLNF----EVIIDEELEKISGGYLPIPDMPGWRGQSTPWWWSLKQSNFSDAYSSFYNATH 59  
WP_023163574                    *:*: **    *:* *:** .*:**     .  .* . :  :  .: :. :.:. .. ::     
 
Enterocin C2 WP_032492334      MKNIKNASNIKVIEDNELKAITGG-GPGKWLP-WLQPAYDFVAGLAKGIGKEGNKNKWKNV- 59 
SL208 Lactococcin-like protein ---MENQLNFEVIIDEELEKISGGYLPIPDMPGWRGQSTPWWWSLKQSNFSDAYSSFYNATH 59 
WP_023163574                      ::*  *::** *:**: *:**  *   :* *   :  :  .* :.  .:. .. :: . 
 
 
 
They are a class II bacteriocins, and many of these bacteriocins had shown to share part 
of their sequences, indicating the fundamental role of these regions for bacteriocin 
activity (Nissen-Meyer et al., 1992). Finally, peak 2 purification, confirmation of its 
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antibacterial activity and a detailed proteomic analyses are further necessary in order to 
attribute it to any of the L. lactis bacteriocins. 
Summing up, the investigation of bacteriocin-related genes of L. lactis subsp. lactis SL208 
genome demonstrated the presence of genes encoding Lacticin 481 and one more 
protein with likely antibacterial properties not yet characterized among the species L. 
lactis antibacterial molecules. The emergence of antibiotic resistant strains make the 
discovery of new antibacterial molecules very attractive for researchers (Dicks et al., 
2011). Furthermore, due to the safety and use in food grade products, the species L. lactis 
is considered advantageous to harbor bacteriocin-encoding genes (Rodriguez et al., 
2003). On the other hand, despite the activity of SL208 CFS against streptococcal strains, 
the lower activity against S. aureus and CNS made the SL208 bacteriocins less attractive 
for further application in bovine mastitis. 
 
4. INTERACTION OF BACTERIOCINS OR LIVE LACTOCOCCAL CULTURES 
WITH MAMMARY EPITHELIAL CELLS 
 
Before to stimulate BME-UV1 cells, the influence of fetal calf serum (FCS) on N-acetil-β-D-
glucosaminidase (NAGase) and Lysozyme (LZ) activity was analyzed: the monolayers were 
maintained for 24h in the medium with or without FCS and then intracellular and 
extracellular activity of both enzymes were measured. The results showed that FCS acted 
as stimulus for enzymes production, in particular NAGase release was higher with 
increasing FCS concentrations (data not shown). On the other hand, active cellular 
metabolism was shown in the cells cultured without FCS, as confirmed by the comparison 
with intracellular levels obtained from cells cultured with FCS: similar intracellular 
amounts could be observed in all cultures with or without FCS. When lysozyme was 
considered, enzyme activity was stable in the course of observation period, 
demonstrating a basal LZ production by mammary epithelial cells in the presence or 
absence of FCS.  
The production of NAGase and LZ by BME-UV1 demonstrated the capability of these cells 
to respond to an inflammatory stimulus, as it happens in the in vivo contest. In order to 
prevent any stimulation by medium components, we decided to add CFSs or live 
lattococci to BME-UV1 in the culture medium without FCS. SL208 strain was used only as 
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live culture, due to the lack of CFS activity against pathogens when the LAB was cultured 
in the cell medium. Before the addiction of LL11 and SL153 CFSs to the cells, their 
antimicrobial activity was assayed with the MIC test and the production of bacteriocins 
was confirmed by the growth inhibition of the S. agalactiaeMB386 reference strain: LL11 
and SL153 bacteriocins showed 128 and 256 AU/mL respectively. 
4.1. N-acetil-β-D-glucosaminidase and Lysozyme assays 
To observe the differences in enzymes production and release, NAGase and LZ activity 
were investigated in the intracellular and extracellular compartment. Figure 4.1 shows 
the comparison of extracellular release and intracellular storage of NAGase and LZ in 
untreated and treated cells. A statistically significant difference was observed for both 
enzymes between the intracellular and extracellular compartment, with higher amounts 
of enzymes stored in the cells. As expected, extracellular amounts of enzymes were never 
higher than intracellular ones, since the enzymes are produced and contained into the 
cells and secreted if an inflammatory stimulus occurs (Kitchen et al., 1981; Ebling et al., 
2001, Zecconi and Smith, 2003). Furthermore, the higher activity of lysosomal enzymes in 
the intracellular compartment of treated cells suggested that cell integrity was 
uninfluenced by treatments.  
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B)  
Figure 4.1 Intracellular enzymes production and extracellular release in untreated (k-) 
CFS-treated (btc treat) and live lactococcal cultures-treated (lc treat) cells. Mean values 
and standard deviations of: A) NAGase (expressed in pmol 4MU/min/Μl) and B) LZ 
(expressed in Units/mL). 
*P<0.05; **P<0.01; ***P<0.001 
 
For the statistical analysis, the first two time points (4h and 8h) were gathered, as well as 
the last two (15h and 24h) in early and late observations respectively. Figure 4.2 shows 
the intracellular NAGase activity: the lack of statistical significance indicated that the 
enzyme activity remained unchanged over the time and unaffected by the treatments. 
Although lower amount for LL11 treated cells and a noticeable standard deviations 
especially in the late time of the study, mean intracellular NAGase remained always 
higher than the extracellular one (Figures 4.2 and 4.3). These results suggested that an 
active cellular metabolism was maintained by the cells during the trial. 
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Figure 4.2 Intracellular NAGase activity in BME-UV1 cells treated with nisin containing-
CFSs (LL11btc and SL153btc) or Lactococcus live cultures (LL11, SL153 and SL208), in the 
A) early observations (t1) and B) late observations (t2) of experiment. 
 
To the contrary, excretion of NAGase was influenced by time (P<0,001) and treatments 
(P<0,001). Due to the statistically significant difference between the two observations, 
the post-hoc test was performed separately for each observation time: in the early 
observation no statistically significant difference was observed when treated cells were 
compared with the control, but a difference was demonstrated among the treatments 
with live culture lactococci (LL11, SL153 and SL208) and the treatments with nisin-
containing CFS (LL11btc and SL153btc). In particular, the secretion of NAGase was higher 
when the cells were treated with the live LL11 strain, rather than with its CFS (P=0,048). 
SL208 live strain-treated cells showed higher amount of extracellular NAGase when 
compared with LL11 and SL153 CFS treatments (P=0,021 and 0,046 respectively), 
indicating an early stimulus for NAGase secretion by live cells but not by nisin-containing 
CFSs. This result was more evident after 15-24h of incubation, when the cells treated with 
LL11 and SL153 showed a 5-fold increment in the release of NAGase (P=0,013 and 
P=0,007 respectively) in comparison with both untreated cells and bacteriocin-treated 
cells (Figure 4.3). 
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Figure 4.3 Extracellular NAGase concentration in BME-UV1 cells treated with nisin 
containing-CFSs (LL11btc and SL153btc) or Lactococcus live cultures (LL11, SL153 and 
SL208), in the A) early observations (t1) and B) late observations of experiment (t2). 
a, b, c Different letters indicate significant difference in enzyme production between 
treatments. 
 
These data suggested a slight inflammatory response of epithelial cells induced by live 
lactococcal cultures, in particular LL11 and SL153 strains. 
NAGase is mainly released from neutrophils during phagocytosis and cell lysis, it is 
considered a marker of tissue damage (Forman et al., 1996) but its increment is also 
associated to an increased lysosomal activity (Bosomworth et al., 1999). Some studies 
demonstrated that NAGase activity in milk increased both in clinical and subclinical 
mastitis (Akerstedt et al.,2012), thus this enzyme can be used as an indicator of mammary 
inflammation and immunity response activation. 
Similarly to NAGase, LZ intracellular accumulation was not influenced by the treatments 
or time: as showed in figure 4.4, similar amounts of intracellular enzyme were detected in 
the treatments and over the time. These results confirmed that cellular metabolism and 
lysosomal activity were maintained by the cells during the trial. 
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Figure 4.4 Intracellular LZ in BME-UV1 cells treated with nisin containing-CFSs (LL11btc 
and SL153btc) or Lactococcus live cultures (LL11, SL153 and SL208), in the A) early 
observations (t1) and B) late observations (t2) of experiment (t2). 
 
A completely different pattern was observed for extracellular LZ, which activity was 
statistically significant influenced by time (P<0,001) and treatments (P<0,001). Due to the 
statistically significant difference between the two observations, the post-hoc test was 
performed separately for each observation time. In the early times (4h and 8h) of the 
experiment, LZ showed similar amounts among the cells treated with live lactococcal 
strains; unexpectedly, LZ activity incremented significantly when cells were treated with 
the nisin-containing CFSs. This increase respect to the control was statistically significant 
(P=0,021 and P=0,005 respectively). To the contrary, after 15h, the extracellular activity of 
this enzyme was higher in the cells treated with SL208 and LL11 live cultures. In particular, 
LL11 treated cells evidenced a statistically significant increment (P<0,001) in LZ activity 
that was almost duplicated (Figure 4.5). 
0
5
10
15
20
25
30
35
40
45
50
55
60
t1 t2
U
n
it
s/
m
L 
k- LL11btc SL153btc LL11 SL153 SL208
A) B) 
69 
 
 
Figure 4.5 Extracellular LZ in BME-UV1 cells treated with nisin containing-CFSs (LL11btc 
and SL153btc) or Lactococcus live cultures (LL11, SL153 and SL208), in the A) early 
observations (t1) and B) late observations (t2) of experiment. 
a, b, c Different letters indicate significant difference in enzyme production between 
treatments. 
 
These results confirmed the stimulation of lysosomal activity by lctococcal strains and, to 
a lesser extent by nisin-containing CFSs, sustained by unaltered amount of both enzymes 
in the intracellular compartment. Although these enzymes increase their activity when an 
inflammation occurs (Sarikaya et al., 2006), it has been shown that in the absence of an 
inflammatory stimulus, the somatic cell count (SCC) is not correlated with NAGase and LZ 
amounts (Piccinnini et al., 2007). Thus, when SCC levels are low, the primary source of 
innate immunity factors could be udder tissues (Bruckmaier, 2005). Therefore, the role of 
epithelial cells should be considered in a preventive approach of mastitis. The stimulation 
of enzymes secretion due to the administration of lactococci or their antibacterial 
products, with consequently potential enhancement of pathogens cleaning, can be of 
interest for the prevention of intramammary infections. 
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4.2. Cytokine expression 
The epithelial cells have both a sentinel and an effector role and they are well suited to 
exert these functions due to their abundance and exposed position to invading 
microorganisms (Günther et al., 2010). BME-UV1 cells express immunological and 
inflammatory molecules (Mazzilli and Zecconi, 2010), furthermore it has been 
demonstrated that they produce proinflammatory cytokines upon stimulation with 
antimicrobial peptides (Tomasinsig et al., 2010). TNFα is long known to elicit both local 
and systemic immune response (Pfeffer, 2003), while IL-8 is a key factor for recruiting 
effector cells of immune defense (polymorphonuclear granulocytes, PMN) into the udder 
(Toshihide, 2003). We examined the effect of bacteriocinogenic lactococcal-strains (LL11, 
SL153 and SL208) and the two nisin-containing CFS on transcriptional levels of those 
cytokines in BME-UV1 cells. 
Figure 4.6 shows the expression of TNFα as a result of the five different treatments. BME-
UV1 response to nisin-containing CFS (LL11btc and SL153btc) was different: cells treated 
with LL11 CFS had a negative expression in comparison with the control at all the time-
points, while cells treated with SL153 CFS showed lower levels of TNFα until 15h and a 
positive expression at 24h of exposure. The increment of TNFα transcription levels in 
epithelial cells after antimicrobial peptide stimulus was previously observed in a study by 
Tomasinsig et al. (2010), which concluded that enhanced TNFα expression triggered the 
activation of other immune system components. Indeed, the moderate increment 
induced by SL153 CFS is more similar to modulation of immune response, than to 
activation of acute phase response. The differences of TNFα stimulation observed 
between SL153 and LL11 CFSs could be attributed to the different amount of nisin 
contained in the CFSs, as elucidated during pathogens sensitivity tests. For the 3 live 
culture treatments, a decreasing tendency was overall demonstrated, with lower levels of 
expression compared to the control. 
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Figure 4.6 TNFα expression (normalized fold expression relative to the control) in BME-
UV1 cells treated with nisin containing-CFSs (LL11btc and SL153btc) or Lactococcus live 
cultures (LL11, SL153 and SL208). The data are the means of two independent 
experiments displayed as difference to the control. 
 
Since the statistical analysis did not show any significant effect of time on TNFα 
expression, the data were analysed grouping all time points (Figure 4.7), to observe the 
effect of the single treatment on the expression levels. That analysis highlighted that 
SL153 live culture treated cells reduced significantly the expression of TNFα in comparison 
with untreated cells, independently of treatment time. 
These results are in agreement with Luerce et al. (2014), who showed the ability of live 
Lactococcus lactis culture to reduce TNFα response in stimulated intestinal epithelial cells 
and also to inhibit IL-8 production when the culture supernatant was applied. They 
observed also that the immunomodulatory response was strain-dependent. Moreover, 
Jensen et al. (2014) observed the strain-specific induction of pro-inflammatory cytokines 
by Lactobacillus species. They also suggested that live culture LABs have the ability to 
secrete  pro-inflammatory and anti-inflammatory mediators. 
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Figure 4.7 Expression levels of the TNFα gene in BME-UV1 untreated (k-) and treated 
cells. Data are showed as means ± standard deviations (SD) of all time point-measures. 
 
IL-8 expression (Figure 4.8) showed a negative, but not significant trend in the cells 
treated with SL153 or LL11 CFSs. 
Also live culture treatments demonstrated negative levels of IL-8 expression, indicating a 
lower expression in comparison with the control. Only LL11 treated cells showed a 
positive relative expression at 15h with 7 fold-changes over the untreated cells, followed 
by a drastic drop in the last time point measurement. 
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Figure 4.8 IL-8 expression (normalized fold expression relative to the control) in BME-UV1 
cells treated with nisin containing-CFSs (LL11btc and SL153btc) or Lactococcus live 
cultures (LL11, SL153 and SL208). The data are the means of two independent 
experiments displayed as difference to the control. 
 
When the four time points were grouped, no statistically significant differences were 
observed between treatments and control, with obvious high standard deviation 
observed in the expression of LL11 live culture-treated cells (Figure 4.9). 
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Figure 4.9 Expression levels of the IL-8 gene in BME-UV1 untreated (k-) and treated cells. 
Data are showed as means ± standard deviations (SD) of all time point-measures. 
 
TNFα is a proinflammatory cytokine stimulating the acute phase reaction and the local 
immune response. Although these local and systemic effects are beneficial to stimulate 
the host innate immune defense against infections (Bannerman, 2014), TNFα causes the 
classical signs of inflammation and is associated with severe symptoms which characterize  
E. coli mastitis (Alluwaimi, 2004). Thus, on one hand TNFα increment could be desirable 
to ensure the activation of immune response, but on the other hand the control of TNFα 
release could be an interesting approach to reduce the symptoms linked to clinical 
intramammary infections. Furthermore, it was demonstrated the capability of TNFα to 
suppress lactogenic function of the glands after infusion (Alluwaimi, 2004). Indeed, it may 
be essential for the mammary gland to keep the expression of TNFα under rigid control, 
because it has an autocrine effect inhibiting the synthesis of caseins by MEC (Shea-Eaton 
et al., 2001). There is also the evidence that both bacterial and host immune factors 
contribute to tissue damage during mastitis with consequent epithelial cells apoptosis 
and decreased milk production (Zhao and Lacasse, 2008). The role of cytokines in tissue 
damage is under investigation and while the therapeutic potential of certain cytokines 
has been proposed (Alluwaimi, 2004) it has been also demonstrated that TNFα and IL-1 
induce apoptosis in different  cell types (Zhao and Lacasse, 2008). TNFα infusion was also 
evaluated to enhance intracellular killing of S. aureus by mammary gland-derived 
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neutrophils and macrophages, but this approach failed its purpose (Sanchez et al., 1994). 
The cytokine-mediated recruitment of neutrophils could be of interest to enhance 
phagocytosis, but PMN also release factors which are responsible for tissue damages. 
Therefore, to protect mammary tissues from oxidative stress due to PMN recruitment 
during mastitis, intramammary treatments often contain anti-inflammatory components 
(Klostermann et al., 2008). 
Due to their high antibacterial activity and their ability to stimulate lysosomal 
metabolism, SL153 and LL11 Lactococcus lactis strains could be of interest for the 
development of intrammary probiotic treatments. In addition, SL153 strain could be 
advantageous for its potential anti-inflammatory properties. Furthermore nisin-
containing CFSs should be considered as alternative treatments to achieve bacterial 
cleaning and stimulate LZ secretion without any cell damage or pro-inflammatory action. 
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CONCLUSIONS 
 
Since bacteriocins produced by LAB display antimicrobial activity against a broad range of 
Gram-positive bacteria and, to a lesser extent, against Gram-negative bacteria, they are 
attracting considerable interest for their potential use as natural and non-toxic 
antimicrobial molecules (Cotter et al., 2005; Deegan et al., 2006). Bacteriocins may be 
useful in human and veterinary applications, therefore they could have an interesting 
development in those preparations requiring safety, residual absence and antimicrobial 
efficacy combination. From a clinical perspective, the emergence of drug-resistant 
pathogens, both in medical treatments and animal production makes the identification of 
novel antimicrobial tools even more important (Cintas et al., 2011). A considerable 
number of bacteriocins have already been described in literature but few studies have 
been performed concerning application of bacteriocins produced by Lactococcus spp. in 
veterinary medicine. Safety and efficacy of molecules produced by Lactococcus spp. 
encourage the efforts in the development of new formulations for mastitis prevention 
and therapy. Moreover, the absence of residues in the milk of treated cows meets the 
increasing request for reduced use of antibiotics and safety and natural food. 
Accordingly to the proposed tasks of this study the following conclusions can be drawn: 
1. The best culture conditions to optimize LAB bacteriocin production were defined 
and the acid-extraction method was shown to efficiently extract their antibacterial 
proteins. 
2. Antibacterial spot-on-lawn is an optimal test to screen large numbers of strains, 
and to select bacteriocinogenic strains, while MIC assay can be successfully 
applied to determine their antibacterial potency. 
3. The efficacy of Lactococcus lactis subsp. lactis LL11, SL153 and SL208 strains was 
demonstrated against mastitis pathogens. 
4. Lactococcus lactis subsp. lactis LL11 and SL153 were found to produce an 
antibacterial protein attributable to Nisin A according its exact mass. The strain 
SL208 potentially produced Lacticin 481 and a novel molecule with likely 
antibacterial activity. Detailed proteomic analyses are further necessary to 
definitely identify this molecules. 
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5. Both live culture strains and their CFSs, displayed the capability to interact in vitro 
with bovine epithelial cells, demonstrating their ability to contribute to immune 
response modulation. 
To our knowledge, this is the first study demonstrating the interaction between lactococci 
or bacteriocins and epithelial cells. 
Further investigations focusing possible resistance development are necessary. 
Antibacterial peptides from Lactococcus spp. are likely to find a niche in the antibiotics 
market. Likewise the effectiveness of live culture treatments against mastitis pathogens  
and their interactions with the innate response open the way for the development of 
probiotic products for mastitis cure and prevention.  
 
 
AKNOWLEDGMENTS 
We thank Dr. Alberto Giardini (Centro Sperimentale del Latte, Zelo Buon Persico-Lodi, IT) 
for providing LAB strains. 
  
78 
 
RINGRAZIAMENTI 
 
Un doveroso ringraziamento alla mia tutor prof. Renata Piccinini per avermi dato 
l’opportunit{ di iniziare e di continuare il mio percorso in Universit{ permettendomi di 
lavorare al suo fianco in laboratorio e di portare a termine questo lavoro. 
 
Ringrazio il prof. Ivano De Noni e il dott. Alberto Giardini per aver arricchito le mie 
competenze con i numerosi incontri e dibattiti, e per l’interesse che hanno sempre dimostrato 
per l’argomento. 
 
Un ringraziamento particolare alla dr.ssa Milda Stuknytė, per l’impegno, la pazienza e la 
professionalità con cui mi ha guidata in campi a me inesplorati e per avermi mostrato il suo 
impeccabile metodo di lavoro. Alla dr.ssa Giulietta Minozzi, per i suoi preziosi commenti, la 
sua disponibilità, la pazienza con cui mi ha trasmesso competenze per me fondamentali. 
Grazie, senza il vostro aiuto questo lavoro non mi avrebbe dato tali soddisfazioni. 
 
Grazie alla dr.ssa Maria Elena Gelain, sempre disponibile anche da lontano a fornirmi le sue 
preziose consulenze e alla dr.ssa Maria Mazzilli, amica oltre che insostituibile sostegno e 
fonte di ispirazione. 
  
79 
 
REFERENCES 
 
1. Åkerstedt M, Forsbäck M, Larsen T, Svennersten-Sjaunja K (2011) Natural variation in 
biomarkers indicating mastitis in healthy cows. J Dairy Res 78:88–96 
2. Alluwaimi AM (2004) The cytokines of bovine mammary gland: prospects for diagnosis 
and therapy. Res Vet Sci 77(3):211–222 
3. Alluwaimi AM, Leutenegger CM, Farver T B, Rossitto  PV, Smith4 WL, Cullor JS (2003) 
The Cytokine Markers in Staphylococcus aureus Mastitis of Bovine Mammary Gland. J 
Vet Med 50(3):105-111 
4. Andrews S (2010) FastQC a quality-control tool for high-throughput sequence data. 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
5. Balciunas EM, Castillo Martinez FA, Todorov SD, Gombossy de Melo Franco BD, 
Converti A, de Souza Oliveira RP (2013) Novel biotechnological applications of 
bacteriocins: A review. Food Control 32: 134-142 
6. Baljinder K, Praveen B, Bharti M, Ashish C, Balvir K and Neena G (2013) Antimicrobial 
Spectrum of Anti-Gardnerella vaginalis Bacteriocin Producing Lactobacillus fermentum 
HV6b Against Bacterial Vaginosis Associated Organisms. Am J Biochem Mol Biol 3:91-
100 
7. Balla E, Dicks LM, Du Toit M, Van Der Merwe MJ, Holzapfel WH (2000). 
Characterization and cloning of the genes encoding enterocin 1071A and enterocin 
1071B, two antimicrobial peptides produced by Enterococcus faecalis BFE 1071. Appl 
Environ Microbiol 66:1298-304 
8. Bannerman DD (2009) Pathogen-dependent induction of cytokines and other soluble 
inflammatory mediators during intramammary infection of dairy cows, J Anim Sci 
87:10-25 
9. Bannerman DD, Paape MJ, Lee JW, Zhao X, Hope JC and Rainard P (2004) Escherichia 
coli and Staphylococcus aureus elicit differential innate immune responses following 
intramammary infection. Clin Diag. Lab Immuno. 11:463–472 
10. Barber M, Yang TJ, (1998) Chemotactic activities in non mastitic and mastitic 
mammary secretions: Presence of interleukin-8 in mastitic but not nonmastitic 
secretions. Clin Diag Lab Immunol 5:82–86 
11. Barkema HW, Deluyker HA, Schukken YH, Lam TJGM (1999) Quarter-milk somatic cell 
count at calving and at the first six milkings after calving. Prev Vet Med 38:1–9 
80 
 
12. Baumgarth N, Tung JW, Herzenberg LA (2005) Inherent specificities in natural 
antibodies: a key to immune defense against pathogen invasion, Springer Semin 
Immunopathol 26 347-362 
13. Beecher C, Daly M, Berry DP, Klostermann K, Flynn J, Meaney W, Hill C, McCarthy TV, 
Ross RP, Giblin L (2009) Administration of a live culture of Lactococcus lactis DPC 3147 
into the bovine mammary gland stimulates the local host immune response, 
particularly IL-1β and IL-8 gene expression. J Dairy Res 76:340-348 
14. Berry EA, Hillerton JE (2000) Dry cow treatment strategies. In: Proceedings of the 39th 
Annual Meeting of the National Mastitis Council, February 13th – 16th. Atlanta GA. pp. 
213-214. National Mastitis Council, Madison, WI 
15. Berry EA, Hillerton JE (2002) The Effect of an Intramammary Teat Seal on New 
Intramammary Infections. J Dairy Sci 85:2512-2520 
16. Bhunia AK, Johnson MC, Ray B (1987) Direct detection of an antimicrobial peptide of 
Pediococcus acidilactici in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
J Ind  Microbiol. 2:319-322 
17. Boes M (2000) Role of natural and immune IgM antibodies in immune responses. Mol 
Immunol 37:1141–1149 
18. Bosomworth MP, Aparicio SR, Hay AWM (1999) Urine N-acetyl-β-glucosaminidase – A 
marker of tubular damage? Nephrol. Dial. Transplant 14:620-626 
19. Bouchard DS, Rault L, Berkova N, Le Loir Y, Even S (2013) Inhibition of Staphyloccoccus 
aureus Invasion into Bovine Mammary Epithelial Cells by Contact with Live 
Lactobacillus casei. Appl Environ Microbiol 79(3):877-885 
20. Boudjellab N, Chan-Tang HS, Li X, Zhao X (1998) Interleukin 8 response by bovine 
mam- mary epithelial cells to lipopolysaccharide stimulation. Am J Vet Res 59:1563–
1567 
21. Bradley AJ (2002) Bovine Mastitis: An Evolving Disease. Vet J.164(2):116-28 
22. Bruckmaier RM (2005) Gene expression of factors related to the immune reaction in 
response to intramammary Escherichia coli lipopolysaccharide challenge. J Dairy Res 
72:120–124 
23. CaoLT, Wu JQ, Xie F, Hu SH, Mo Y (2007)Efficacy of nisin in treatment of 
clinicalmastitis in lactating dairy cows. J Dairy Sci 8:3980-3985 
24. Chevreux B, Wetter T, Suhai S (1999) Genome sequence assembly using trace signals 
and additional sequence information. Computer science and biology: proceedings of 
the German Conference on Bioinformatics (GCB) 99:45–56 
81 
 
25. Cintas LM, Herranz C, Hernàndez PE (2011) Natural and Heterologous Production of 
Bacteriocins– Prokaryotic Antimicrobial Peptides, from Genes to Applications. 
Springer, eds Drider D, Rebuffat S, pp. 115-143 
26. Clinical and Laboratory Standards Institute (2008) Performance standards for 
antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; 
approved standards (M31-A3). CLSI, Wayne, PA, USA 
27. Collins B, Cotter PD, Hill C, Ross RP (2010) Applications of Lactic Acid Bacteria-
Produced Bacteriocins – Biotechnoligies of Lactic Acid Bacteria, novel applications. 
Wiley-Blackwell, eds Mozzi F, Raya RR, Vignolo GM, pp. 8989-109. 
28. Cotter PD, Hill C, Ross RP (2005) Bacteriocins: developing innate immunity for food. 
Nat Rev Microbiol 3:777–788 
29. Cross ML (2002) Microbes versus microbes: immune signals generated by probiotic 
lactobacilli and their role in protection against microbial pathogens. FEMS Immun 
Medical Microbiol 34:245-253 
30. De Vuyst L, Vandamme EJ (1991) Microbial manipulation of nisin biosynthesis and 
fermentation – Nisin and Novel Antibiotics. Jung G and Sahl, ESCOM Science 
Publishers, pp. 398-409 
31. Deegan LH, Cotter PD, Hill C, Ross P (2006) Bacteriocins: Biological tools for bio-
preservation and shelf-life extension. Int Dairy J 16:1058-1071 
32. Dicks LMT, Heunis TDJ, van Staden DA, Brand A, Sutyak Noll K, Chikindas ML (2011) 
Medical and Personal Care Applications of Bacteriocins Produced by Lactic Acid 
Bacteria – Prokaryotic Antimicrobial Peptides, from Genes to Applications. Springer, 
eds Drider D, Rebuffat S, pp. 391-437 
33. Didier A, Kessel S (2004) Novel in-vitro co-culture system for studies on leukocyte-
mammary gland epithelial cell cross-talk. Milchwissenschaft-Milk Science 
International 59:236–239 
34. Drider D, Fimland G, Héchard Y, McMullen LM, Prevost H (2006) The continuing 
history of classIIa bacteriocins. Microbiol Mol Biol Rev 70:564–582 
35. Ebling TL, Fox LK, Bayles KW, Bohach GA, Byrne KM, Davis WC, Ferens WA, Hillers JK 
(2001) Bovine mammary immune response to an experimental intramammary 
infection with a Staphylococcus aureus strain containing a gene for staphylococcal 
enterotoxin C1. J Dairy Sci 84(9):2044-50 
36. EFSA (2006) Opinion of the Scientific Panel on Food Additives, Flavourings, Processing 
Aids and Materials in Contact with Food on a request from the Commission related to 
the use of nisin (E 234) as a food additive. The EFSA Journal 314: 1-16 
82 
 
37. Fitzgerald DC, Meade KG, McEvoy AN, Lillis L, Murphy EP, Machugh DE, Baird AW 
(2007) Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB 
(NFk-B) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial 
cells. Vet Immunol Immunop 116:59–68 
38. Forman MF, Beck MM, Kachman D (1996) N-acetyl-β-glucosaminidase as a Marker of 
Renal Damage in Hens, Poultry Science 75:1563-1568 
39. Frola ID, Pellegrino MS, Espeche MC, Giraudo JA, Nader-Macias MEF, Bogni CI (2012) 
Effects of intramammary inoculation of Lactobacillus perolens CRL1724 in lactating 
cows’ udders. J Dairy Res 79:84-92. 
40. Frola ID, Pellegrino MS, Magnano G, Giraudo JA, Espeche MC, Nader-Macias MEF, 
Bogni CI (2013) Histological examination of non-lactating bovine hudders inoculated 
with Lactobacillus perolens CRL 1724. J Dairy Res 80:28-35. 
41. Ganz T (2004) Antimicrobial polypeptides. J Leukoc Biol 75(1):34-38 
42. Guinane CM, Cotter PD, Hill C, Ross RP (2006) Spontaneous resistance in Lactococcus 
lactis IL1403 to the lantibiotic lacticin 3147. FEMS Microbiol Lett 260:77-83. 
43. Günther J, Liu S, Esch K, Schuberth HJ, Seyfert HM (2010) Stimulated expression of 
TNF-α and IL-8, but not of lingual antimicrobial peptide reﬂects the concentration of 
pathogens contacting bovine mammary epithelial cells. Vet Immunol Immunopathol 
135:152–157 
44. Hagiwara K, Yamanaka H, Hisaeda K, Taharaguchi S, Kirisawa R, Iwai H (2001) 
Concentrations of IL-6 in Serum and Whey from Healthy and Mastitic Cows, Vet Res 
Comm 25(2):99-108 
45. Hames BD ed. (1998) Gel Electrophoresis of Proteins: A Pratical Approach, 3rd edn. 
Oxford University Press, New York (USA) 
46. Hancock REW, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-
infective therapeutic strategies. Nat Biotechnol 24:1551-1557 
47. Hillerton JE (1999) Redefining mastitis based on somatic cell count. IDF Bulletin 345:4–
6 
48. Hogan JS, Gonzales RN, Harmon RJ, Nickerson SC, Oliver SP, Pankey JW & Smith KL 
(1999) Laboratory Handbook on Bovine Mastitis, revised edition. National Mastitis 
Council Inc. Madison WI, p. 222 
49. Hogan JS, Pankey JW, Duthie AH (1987) Growth inhibition of mastitis pathogens by 
long-chain fatty acids. J Dairy Sci. 70:927-934 
83 
 
50. Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van 
Nuland NA (2004) The nisin-lipid II complex reveals a pyrophosphate cage that 
provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11:963-967 
51. Ibrahim HR, Higashiguchi S, Koketsu M, Juneja LR, Kim M, Yamamoto T (1996). A 
structural phase of heat-denatured lysozymewith novel antimicrobial action. J Agr 
Food Chem 44:1416–1423 
52. Jensen H, Drømtorp SM, Axelsson L, Grimmer S (2014). Immunomodulation of 
Monocytes by Probiotic and Selected Lactic Acid Bacteria. Probiotics Antimicrob 
Proteins. [Epub ahead of print] 
53. Jung G (1991) Lantibiotics—Ribosomally Synthesized Biologically Active Polypeptides 
containing Sulfide Bridges and α,β-Didehydroamino Acids. Angew Chem Int Ed Engl 
30:1051-1192 
54. Kitchen B (1981) Review of the progress of dairyscience: Bovine mastitis: Milk 
compositional changes and related diagnostic tests. J Dairy Res 48:167–188 
55. Kitchen B, Kwee WS, Middleton G, Andrews RJ (1984) Relationship between the 
levelof N-acetyl-β-D-glucosaminidase (NAGase) in bovine milk and the presence of 
mastitis pathogens, J Dairy Res 51:11–16. 
56. Klaenhammer TR (1993) Genetics of bacteriocins produced by lactic acid bacteria. 
FEMS Microbiol Rev 12:39–85 
57. Klostermann K, Crispie F, Flynn J, Meaney WJ, Paul Ross R, Hill C (2010) Efficacy of a 
teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-positive pathogens 
associated with bovine mastitis. J Dairy Res 77:231-238 
58. Klostermann K, Crispie F, Flynn J, Ross RP, Hill C, Meaney W (2008) Intramammary 
infusion of a live culture of Lactococcus lactis for treatment of bovine mastitis: 
comparison with antibiotic treatment in field trials. J Dairy Res 75:365-373 
59. Kramer NE,  van Hijum SAFT, Knol J,  Kok J and  Kuipers OP (2006) Transcriptome 
Analysis Reveals Mechanisms by Which Lactococcus lactis Acquires Nisin Resistance. 
Antimicrob Agents Chemother 50 (5): 1753-1761 
60. Laevens H, Deluyker H, Schukken YH, de Meulemeester L, Vandermeersch R, de 
Muelenaere E, de Kruif A (1997) Influence of parity and stage of lactation on the 
somatic cell count in bacteriologically negative cows. J Dairy Sci 80:3219–3226 
61. Lahouassa H., Moussay E., Rainard P., Riollet C. (2007) Differential cytokine and 
chemokine responses of bovine mammary epithelial cells to Staphylococcus aureus 
and Escherichia coli. Cytokine 38:12–21 
84 
 
62. Lauzon K, Zhao X, Bouetard A, Delbecchi L, Paquette B, Lacasse P (2005) Antioxidants 
to prevent bovine neutrophil induced mammary epithelial cell damage. J. Dairy Sci 
88:4295-4303 
63. Liu W, Hansen JN (1990) Some chemical and physical properties of nisin, a small-
protein antibiotic produced by Lactococcus lactis. Appl Environ Microbiol 56(8):2551-
2558 
64. Lohans CT, Vederas JC (2012) Development of Class IIa Bacteriocins as Therapeutic 
Agents. Int J Microbiol 38:6410 
65. Lopez Expósito I, Recio I (2006) Antimicrobial activity of peptidesand folding variants 
from milk proteins. Int Dairy J, 16: 1294-1305 
66. Luerce TD, Gomes-Santos AC, Rocha CS, Moreira TG, Cruz DN, Lemos L, Sousa AL, 
Pereira VB, de Azevedo M, Moraes K, Cara DC, LeBlanc JG, Azevedo V, Faria AM, 
Miyoshi A (2014) Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during 
the remission period of chemically induced colitis. Gut Pathog 29:6-33 
67. Macwana SJ, Muriana PM (2012) A ‘bacteriocin PCR array’ for identification of 
bacteriocin-related structural genes in lactic acid bacteria. J Microbiol Methods, 88: 
197-204 
68. Maldonado-Barragan A, Caballero-Guerrero B, Jimenez E, Jimenez-Diaz R, Ruiz-Barba 
JL, Rodriguez JM (2009) Enterocin C, a class IIb bacteriocin produced by E. faecalis 
C901, a strain isolated from human colostrum. Int JJ Food Microbiol 133:105-112 
69. Mantovani HC, Russel JB (2001) Nisin resistance of Sreptococcus bovis. Appl Environ 
Microbiol, 67: 808-813 
70. Matitashvili E, Bramley AJ, Zavizion B (1997) An in vitro approach to ruminant 
mammary gland biology. Biotechnol Adv, 15: 17-41 
71. Mattila T, Syväjärvi J, Sandholm M (1986) Milk antitrypsin, NAGase, plasmin and 
bacterialreplication rate in whey – effects of lactationstage, parity and daily milk yield. 
J Vet Med B, 33 :462–470 
72. Mazzilli M, Zecconi A (2010) Assessment of epithelial cells immune and inflammatory 
response to Staphylococcus aureus when exposed to a macrolide. J Dairy Res 77:404-
410 
73. Mc Entire JC, Carman GM and Montville J (2004) Increased ATPase activity is 
responsible for acid sensitivity of nisin-resistant Listeria monocytogenes ATCC 700302. 
Appl Environ Microbiol 70:2717-2721 
85 
 
74. Mehrzad J, Janssen D, Duchateau L, Burvenich C (2008) Increase in Escherichia coli 
inoculum dose accelerates CD8+ T-cell trafficking in the primiparous bovine mammary 
gland. J Dairy Sci 91:193–201 
75. Miles H, Lesser W, Sears P (1992) The Economic Implications of Bioengineered 
Mastitis Control. J Dairy Sci 75: 596-605 
76. Molenaar AJ, Kuys YM, Davis SR, Wilkins RJ, Mead PE, Tweedie JW (1996) Elevation of 
lactoferrin gene expression in developing, ductal, resting and regressing parenchymal 
epithelium of the ruminat mammary gland, J Dairy Sci 79:1198-1208 
77. Muhle SA, Tam JP (2001) Design of Gram-negative selective antimicrobial peptides. 
Biochem 40: 5777–5785 
78. Neghmouchi K, Kheadr E, Lacroix C, Fliss I (2007) Class I/Class IIa bacteriocin cross-
resistance phenomenon in Listeria monocytogenes. Food Microbiol 24:718-727. 
79. Nissen-Meyer J, Holo H, Håvarstein LS, Sletten K, Nes IF (1992). A novel lactococcal 
bacteriocin whose activity depends on the complementary action of two peptides. J 
Bacteriol. 174:5686-5692 
80. Ohtsuka H, Kudo K, Mori K, Nagai F, Hatsugaya A, Tajima M, Tmaura K, Hoshi F., Koiwa 
M, Kawamura S (2001) Acute phase response in naturally occurring coliform mastitis. J 
Vet Med Sci 63:675–678 
81. Oliver SP, Hogan JS, Jayarao BM, and Owens WE (2004). Microbiological Procedures 
for the Diagnosis of Bovine Udder Infection and Determination of Milk Quality. 4th ed. 
National Mastitis Council Inc, Verona, WI 
82. Osma KM, Hassan HM, Ibrahim IM, Mikhail MMS (2010) The impact of staphylococcal 
mastitis on the level of milk IL-6, lysozyme and nitric oxide. Comp Immun Microbiol 
Infect Dis 33:85-93 
83. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res 29(9):e45 
84. Pfeffer K (2003) Biological functions of tumor necrosis factor cytokines and their 
receptors. Cytokine Growth Factor Rev 14:185–191. 
85. Piard JC, Kuipers OP, Rollema HS, Desmazeaud MJ, de Vos WM (1993) Structure, 
organization, and expression of the lct gene for lacticin 481, a novel lantibiotic 
produced by Lactococcus lactis. J Biol Chem 268:16361-16368 
86. Piccinini R, Binda E, Belotti M (2007) Evaluation of milk components during whole 
lactation in healthy quarters. J Dairy Res 74: 226-232 
86 
 
87. Pieterse R, Todorov SD, Dicks LMT (2010) Mode of action and in vitro susceptibility of 
mastitis pathogens to macedocin ST91KM and preparation of a teat seal containing 
the bacteriocin. Braz J Microbiol 41:133-145 
88. Pieterse R, TodorovSD (2010) Bacteriocins – Explorating alternatives to antibiotics in 
mastitis treatment. Braz J Microbiol 41: 542-562 
89. Pieterse R, TodorovSD, Dicks LMT (2010) Mode of action and in vitro susceptibility of 
mastitis pathogens to macedocin ST91KM and preparation of a teat seal containing 
the bacteriocin. Braz J Microbiol 41:133-145 
90. Piper C, Draper LA, Cotter PD, Ross RP, Hill C (2009) A comparison of the activities of 
lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus 
species. J Antimicrob Chemother 64:546-551 
91. Piper C, Hill C, Cotter PD, Ross RP (2011) Bioengineering of a Nisin A-producing 
Lactococcus lactis to create isogenic strains producing the natural variants Nisin F, Q 
and Z. MicrobialBiotechnology 4:375-382 
92. Pyörälä S (2003) Indicators of inflammation in the diagnosis of mastitis. Vet Res 
34:565–578 
93. Rainard P (2003) The complement in milk and defense of the bovine mammary gland 
against infection. Vet Res 34:647-670 
94. Riley MA, Wertz JE (2002) Bacteriocins: evolution, ecology, and application. Annu Rev 
Microbiol 56:117–137 
95. Riollet C, Rainard P, Poutrel B (2005) Differential induction of complement fragment 
c5a and inflammatory cytokine during intramammary infections with Escherichia Coli 
and Stapylococcus aureus. Clin Diagn Lab Immunol 7:161-167 
96. Rodriguez JM, Martinez MI, Horn N, Dodd HM (2003) Heterologous production of 
bacteriocins by lactic acid bacteria. Int J Food Microbiol 80:101–116 
97. Ryan MP, Meaney WJ, Ross RP, Hill C (1998) Evaluation of lacticin 3147 and a teat seal 
containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ 
Microbiol. 64:2287-2290 
98. Saavendra L, Sesma F (2011) Purification Techniques of Bacteriocins from Lactic Acid 
Bacteria and Other Gram-Positive Bacteria - Prokaryotic Antimicrobial Peptides, from 
Genes to Applications. Springer, eds Drider D, Rebuffat S, pp. 99-113 
87 
 
99. Sanchez MS, Ford CW, Yancey JR (1994). Effect of tumor necrosis factor-, interleukin-
1β and antibiotics on the killing of intracellular Staphylococcus aureus. J. Dairy Sci. 77: 
1251–1258 
100. Sarikaya H, Schlamberger G, Meyer HHD, Bruckmaier RM (2006) Leukocyte 
populations and mRNA expression of inflammatory factors in quarter milk fractions at 
different somatic cell score levels in dairy cows. Journal of Dairy Science 89:2479–
2486 
101. Sawa N, Zendo T, Kiyofuji J, Fujita K, Himeno K, Nakayama J, Sonomoto K. (2009) 
Identification and characterization of lactocyclicin Q, a novel cyclic bacteriocin 
produced by Lactococcus sp. strain QU 12. Appl Environ Microbiol 75:1552-1558 
102. Schukken Y, Gunther J, Fitzpatrik J, Fontain MC, Goetze L, Holst O, Leight J, Petzl W, 
Schubert HJ, Sipka A, Smith DGE, Quesnell R, Watts J, Yancey R, Zerbe H, Gurjar A, 
Zadoks RN, Seyefert HM (2011) Host- response patterns of intramammary infections 
in dairy cows. Vet Immunol and Immunophatol 144:270-289  
103. Sears PM, Smith BS, Stewart WK, Gonzalez RN, Rubino SD, Gusik SA, Kulisek ES, Projan 
SJ, Blackburn P (1992) Evaluation of a nisin-based germicidal formulation on teat skin 
of live cows. J Dairy Sci 75:3185-3190 
104. Shea-Eaton WK, Lee PP, Ip MM (2001) Regulation of milk protein gene expression in 
normal mammary epithelial cells by tumor necrosis factor. Endocrinology  142:2558–
2568. 
105. Shuster D E, Kehrli ME Jr, Rainard P, Paape M (1997) Complement fragment C5a and 
inflammatory cytokines in neutrophil recruitment during intramammary infection 
with Escherichia coli. Infect Immun 65 (8):3286-3292 
106. Sordillo L.M., Streichter K.L.(2002) Mammary gland immunity and mastitis 
susceptibility. J Mammary Gland Biol Neoplasia 7:135-146 
107. Sparo MD, Castro MS, Andino PJ, Lavigne MV, Ceriani C, Gutierrez GL, Fernandez MM, 
De Marzi MC, Malchiodi EL and Manghi MA (2006) Partial characterization of 
enterocin MR99 from a corn silage isolate of Enterococcus faecalis. J of Appl Microbiol 
100:123–134 
108. Strandberg Y, Gray C, Vuocolo T, Donaldson L, Broadway M, Tellam R (2005) Lipopoly- 
saccharide and lipoteichoic acid induce different innate immune responses in bovine 
mammary epithelial cells. Cytokine 31:72–86 
109. Taverniti V, Stuknyte M, Minuzzo M, Arioli S, De Noni I, Scabiosi C, Cordova ZM, 
Junttila I, Hamalainen S, Turpeinen H, Mora D, Karp M, Pesu M, Guglielmetti S (2013) 
88 
 
S-layer protein mediates the stimulatory effect of Lactobacillus helveticus MIMLh5 on 
innate immunity. App Enviro Microbio 79:1221–1231. 
110. The Clinical and Laboratory Standards Institute (CLSI) (1999). Barry AL, Craig WA, 
Nadler H, Reller LB, Sanders CC,  Swenson JM Methods for Determining Bactericidal 
Activity of Antimicrobial Agents; Approved Guideline. Vol 19 Num 18. 
111. Tizard IR (2013) Innate Immunity: Proinflammatory and Antimicrobial Mediators- 
Veterinary Immunology, 9th edition. Saunders, Philadelphia (PA) pp. 21-29. 
112. Tomasinsig L, De Conti G, Skerlavaj B, Piccinini R, Mazzilli M, D'Este F, Tossi A, Zanetti 
M (2010) Broad-spectrum activity against bacterial mastitis pathogens and activation 
of mammary epithelial cells support a protective role of neutrophil cathelicidins in 
bovine mastitis. Infect Immun. 78(4):1781-8 
113. Torben L and Karen A (2012) Optimizing the fluorometric β-glucuronidase assay in 
ruminant milk for a more precise determination of mastitis. J Dairy Res 79: 7–15. 
114. Toshihide N (2003). Expression of potential lymphocyte trafﬁcking mediator molecules 
in the mammary gland. Vet. Res, 34:3–10. 
115. Twomey DP, Wheelcock AI, Flynn J, Meaney WJ, Hill C, Ross RP (2000) Protection 
against Staphylococcus aureus Mastitis in Dairy Cows Using a Bismuth-Based Teat Seal 
Containin the Bacterioci 3147. J Dairy Sci, 83: 1981-1988 
116. Uguen P, Hindré T, Didelot S, Marty C, Haras D, Le Pennec JP, Vallée-Réhel K, Dufour A (2005) 
Maturation by LctT Is Required for Biosynthesis of Full-Length Lantibiotic Lacticin 481. Appl. 
Environ. Microbiol 71:562-565 
117. Van Knegsel ATM, De Vries Reilingh G, Meulenberg S, Van den Brand H, Dijkstra J, 
Kemp B, Parmentier HK (2007) Natural antibodies related to energy balance in early 
lactation dairy cows. J Dairy Sci 90:5490–5498 
118. Venema K, Abee T, Haandrikman AJ, Leenhouts KJ, Kok J, Konings WN, Venema G. 
(1993) Mode of action of lactococcin B, a thiolactivated bacteriocin from Lactococcus 
lactis. Appl Environ Microbiol 59:1041–1048  
119. Waller KP, Colditz IG, Lun S, Östensson K (2003) Cytokines in mammary lymph and 
milk during endotoxin-induced bovine mastitis. Res Vet Sci 74(1):31-36 
120. Wellnitz O, Kerr DE (2004) Cryopreserved bovine mammary cells to model epithelial 
response to infection. Vet Immunol Immunopathol 101:191–202. 
121. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG 
(2001) Specific binding of nisin to the peptidoglycan precurson lipid II combines pore 
89 
 
formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol 
Chem 276:1772-1779 
122. Wijga S, Bovenhuis H, Bastiaansen JWM, van Arendonk JAM, Ploegaert TCW, Tijhaar E, 
Van der Poel JJ (2013) Genetic parameters for natural antibody isotype titers in milk of 
Dutch Holstein-Friesians. Anim Genet 44(5):485-92 
123. Wu J, Hu S, Cao L (2007) Therapeutic effect of nisin Z on subclinical mastitis in 
lactating cows. Antimicrob Agents Chemother. 9:3131-3135 
124. Yang R, Johnson MC, Ray B (1992) Novel method to extract large amounts of 
bacteriocins from lactic acid bacteria. Appl Environ Microbiol 1992 58:3355-3359 
125. Zavizion B, Gorewit RC, Politis I (1994) Subcloning the MAC-T Bovine Mammary 
Epithelial Cell Line: Morphology, Growth Properties, and Cytogenetic Analysis of 
Clonal Cells. J of Dairy Sci 78:515-527 
126. Zavizion B, van Duffelen M, Shaeffer W, Politis I (1996) Establishment and 
characterization of bovine mammary epithelial cell line with unique properties. In 
vitro Cell Dev Biol Animal 32:138-48 
127. Zecconi A, Smith KL (2003) Ruminant Mammary Gland Immunity. Bruxelles: FIL-IDF 
128. Zendo T, Yoneyama F, Sonomoto K (2010) Lactococcal membrane-permeabilizing 
antimicrobial peptides. Appl Microbiol Biotechnol 88:1-9 
129. Zhao X, Lacasse PJ (2008) Mammary tissue damage during bovine mastitis: causes and 
control. Anim Sci 86:57-65 
  
90 
 
ATTACHMENTS 
 
Attachment A –Scientific activity 
 
 Conte F., Piccinini R., Malvisi M., Foti M.,  Giacopello C., Fisichella V., Cascio O. 
Studio sull’attività antibatterica del lisozima del latte d’asina. Aspetti igienico-
sanitari. LXV Convegno nazionale SISVet (Società Italiana delle Scienze 
Veterinarie), Vibo Valentia 7-10 settembre 2011 
 Malvisi M., Giardini A., Zecconi A., Piccinini R. Preliminary results of antimicrobial 
activity of bacteriocins secreted by lactic acid bacteria against mastitis pathogens. 
Poster presentation, International Scientific Conference on Bacteriocins and 
Antimicrobial Peptides (BAMP2012), Kosice – SK  21-23 Febbraio 2012 
 Malvisi M., Giardini A., Zecconi A., Piccinini R. Attivita' antimicrobica di 
batteriocine prodotte da lactococcus spp. Nei confronti di batteri patogeni della 
mammella bovina. Poster presentation, 3° Congresso lattiero-caseario 
Associazione Italiana Tecnici del Latte (AITeL), Milano 28 settembre 2012 
 Conte F., Foti M., Malvisi  M., Giacopello C., Piccinini R. (2012) Valutazione 
dell’azione antibatterica del lisozima del latte d’asina. Considerazioni igienico - 
sanitarie. Large Animal Review 18:13-16 
 Malvisi M., Giardini A., Zecconi A., Piccinini R. (2013) Attivita' antimicrobica di 
batteriocine prodotte da Lactococcus spp. nei confronti di batteri patogeni della 
mammella bovina. Scienza e Tecnica Lattiero-Casearia 64 (5-6):167-172  
 Pilla R., Malvisi M., Snel G.G., Schwarz D., König S., Czerny C.P., Piccinini R. (2013) 
Differential cell-count as an alternative method to diagnose dairy cow mastitis.J 
Dairy Sci. 96(3):1653-60 
 Pilla R., Snel G.G., Malvisi M., Piccinini R. (2013) Duplex real-time PCR assay for 
rapid identification of Staphylococcus aureus isolates from dairy cow milk.J Dairy 
Res 80:223–226 
 Pilla R., Bonura C., Malvisi M., Snel G.G., Piccinini R. (2013) Methicillin-resistant 
Staphylococcus pseudintermedius as causative agent of dairy cow mastitis. 
Veterinary record. Vet Rec 173(1):19 
 Piccinini R., Malvisi M., Cremonesi P., Capra E., Bignoli G., Castiglioni B., Valentino 
L., Pozzi F., Vezzoli F., Luini M. Prevalence of methicillin-resistant Staphylococcus 
aureus (MRSA) in Italian dairy herds. Intervento presentato al convegno 3rd ASM-
91 
 
ESCMID Conference on Methicillin-resistant Staphylococci in Animals: Veterinary 
and Public Health Implications, 2013 Copenhagen. 
  Snel G.G. , Malvisi M., Pilla R., Piccinini R.  (2014) Evaluation of biofilm formation 
using milk in a flow cell model and microarray characterization of Staphylococcus 
aureus strains from bovine mastitis. DOI: 10.1016/j.vetmic.2014.09.020 
  
92 
 
Attachment B –Supplementary material 
 
Figure S1. HR-MS spectrum (A) and deconvoluted MS spectrum (B) of L. lactis subsp. lactis 
SL153 partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentate peak 
eluting at 11.8 min. 
 
  
93 
 
Figure S2. HR-MS spectrum and deconvoluted MS spectrum of L. lactis subsp. lactis SL153 
partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentate peak eluting 
at 11.5 min. 
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Figure S3. HR-MS spectrum (A) and deconvoluted MS spectrum (B) of L. lactis subsp. lactis 
SL208 partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentate peak 
eluting at 11.8 min. 
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Figure S4. HR-MS spectrum (A) and deconvoluted MS spectrum (B) of L. lactis subsp. lactis 
SL208 partially purified bacteriocin extract (sample B) 1 kDa ultrafiltration retentate peak 
eluting at 6.1 min. 
 
 
